

CITATION REPORT

List of articles citing

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

DOI: 10.1038/nm730

Nature Medicine, 2002, 8, 793-800.

Source: <https://exaly.com/paper-pdf/34732971/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2216	.		
2215	Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. 2002 , 196, 1393-8		91
2214	Expression of programmed death 1 ligands by murine T cells and APC. 2002 , 169, 5538-45		722
2213	Noninterferon-based adjuvant therapy for high-risk melanoma. 2002 , 2, 547-62		2
2212	Tumor-mediated apoptosis of cancer-specific T lymphocytes--reversing the "kiss of death"?. 2002 , 2, 169-71		9
2211	New regulatory co-receptors: inducible co-stimulator and PD-1. 2002 , 14, 779-82		189
2210	Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. 2002 , 9, 1022-35		119
2209	Natural selection of tumor variants in the generation of "tumor escape" phenotypes. 2002 , 3, 999-1005		799
2208	Protect the killer: CTLs need defenses against the tumor. <i>Nature Medicine</i> , 2002 , 8, 787-9	50.5	18
2207	Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. <i>Nature Medicine</i> , 2002 , 8, 1039-1039	50.5	705
2206	Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation. 2003 , 28, 49-59		22
2205	Measurement of CTL-induced cytotoxicity: the caspase 3 assay. 2003 , 8, 563-71		44
2204	CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts. 2003 , 442, 218-25		11
2203	Immunology of B7-H1 and its roles in human diseases. 2003 , 78, 321-8		33
2202	Modulation of costimulation to enhance tumor immunity. 2003 , 52, 663-9		17
2201	Therapeutic vaccination with tumor cells that engage CD137. 2003 , 81, 71-86		22
2200	B7-H1 pathway and its role in the evasion of tumor immunity. 2003 , 81, 281-7		223

2199	Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. 2003 , 97, 2203-11	31
2198	Negative T cell costimulation and islet tolerance. 2003 , 19, 179-85	17
2197	Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. 2003 , 33, 2773-82	111
2196	Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. 2003 , 33, 2706-16	456
2195	Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. 2003 , 15, 725-30	44
2194	The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. 2003 , 4, 899-906	413
2193	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. <i>Nature Medicine</i> , 2003 , 9, 562-7	50.5 980
2192	Targeting tumours with genetically enhanced T lymphocytes. 2003 , 3, 35-45	390
2191	Immunologic principles and immunotherapeutic approaches in ovarian cancer. 2003 , 17, 1051-73	16
2190	Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. 2003 , 112, 837-49; quiz 850	39
2189	Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. 2003 , 198, 851-62	869
2188	B7 family molecules are favorably positioned at the human maternal-fetal interface. 2003 , 68, 1496-504	155
2187	The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. 2003 , 198, 63-9	592
2186	Finding genes for SLE: complex interactions and complex populations. 2003 , 21, 117-20	7
2185	Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. 2003 , 171, 4156-63	138
2184	B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. 2003 , 197, 1721-30	122
2183	Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. 2003 , 197, 1083-91	233
2182	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. 2003 , 100, 5336-41	452

2181	Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. 2003 , 17, 1892-4	90
2180	B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. 2003 , 170, 3637-44	222
2179	Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. 2003 , 198, 31-8	132
2178	Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. 2003 , 198, 71-8	393
2177	Novel approaches to therapeutic cancer vaccines. 2003 , 2, 517-32	15
2176	B7x: a widely expressed B7 family member that inhibits T cell activation. 2003 , 100, 10388-92	317
2175	Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. 2003 , 171, 6929-35	97
2174	Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. 2003 , 171, 4574-81	88
2173	Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. 2003 , 171, 4650-4	210
2172	Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. 2003 , 170, 711-8	219
2171	Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137. 2004 , 101, 4990-5	33
2170	B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. 2004 , 10, 5094-100	569
2169	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. 2004 , 101, 17174-9	657
2168	B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. 2004 , 172, 2530-41	121
2167	Handbook of Cancer Vaccines. 2004 ,	5
2166	Altering immune tolerance therapeutically: the power of negative thinking. 2004 , 75, 586-99	16
2165	Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages. 2004 , 173, 1240-8	159
2164	Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. 2004 , 173, 4919-28	94

2163	PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. 2004 , 64, 1140-5	599
2162	PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. 2004 , 101, 10691-6	474
2161	Cancer immunotherapy: breaking the barriers to harvest the crop. <i>Nature Medicine</i> , 2004 , 10, 887-92	50.5 110
2160	The promise of cancer vaccines. 2004 , 4, 401-11	221
2159	Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. 2004 , 4, 336-47	982
2158	Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. 2004 , 18, 1223-30	49
2157	Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. 2004 , 155, 172-82	215
2156	New B7 family members with positive and negative costimulatory function. 2004 , 4, 8-14	23
2155	PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. 2004 , 230, 89-98	60
2154	Investigation on the effects of soluble programmed death-1 (sPD-1) enhancing anti-tumor immune response. 2004 , 24, 531-4	9
2153	Tumour escape: antitumour effectors too much of a good thing?. 2004 , 53, 262-74	78
2152	Costimulation-based immunotherapy for head and neck cancer. 2004 , 5, 27-33	11
2151	On the pathogenesis of autoimmune thyroid disease: a unifying hypothesis. 2004 , 60, 397-409	47
2150	Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. 2004 , 34, 1892-900	12
2149	Commentary: Regulated equilibrium between opposite signals: a general paradigm for T cell function?. 2004 , 34, 2084-8	9
2148	Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. 2004 , 40, 1312-21	228
2147	Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. 2004 , 6, 759-66	99
2146	The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. 2004 , 94, 215-22	58

2145	Current developments of immunotherapy in the clinic. 2004 , 16, 130-6	65
2144	The regulation of lymphocyte activation by inhibitory receptors. 2004 , 16, 328-36	81
2143	Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. 2004 , 18, 193-209	72
2142	Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. 2004 , 22, 1136-51	254
2141	Using antibodies in tumour immunotherapy. 2004 , 4, 1265-84	7
2140	Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. 2004 ,	
2139	The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. 2004 , 126, 1347-57	118
2138	Cooperative translational control of gene expression by Ras and Akt in cancer. 2004 , 10, 607-13	46
2137	Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. 2004 , 40, 102-9	58
2136	In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. 2004 , 104, 2124-33	134
2135	Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. 2004 , 20, 13-24	18
2134	B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. 2005 , 16, 1081-5	81
2133	The Pulmonary Dendritic/Langerhans Cell in Immunity and Disease. 2005 , 12, 84-89	1
2132	NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. 2005 , 105, 2428-35	104
2131	Induction of tumor NK-cell immunity by anti-CD69 antibody therapy. 2005 , 105, 4399-406	46
2130	B7-H1 connection of innate and adaptive immunity against tumor dormancy. 2005 , 105, 2242-2243	4
2129	Metabolic mechanisms of tumor resistance to T cell effector function. 2005 , 31, 107-18	14
2128	The B7 family revisited. 2005 , 23, 515-48	1861

2127	Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. 2005 , 68, 2091-102	41
2126	Characterization and application of two novel monoclonal antibodies against 2IgB7-H3: expression analysis of 2IgB7-H3 on dendritic cells and tumor cells. 2005 , 66, 83-92	28
2125	Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. 2005 , 130, 809-24	37
2124	Galectins as modulators of tumour progression. 2005 , 5, 29-41	1124
2123	Immunosuppressive networks in the tumour environment and their therapeutic relevance. 2005 , 5, 263-74	1627
2122	Development and immunophenotyping of squamous cell carcinoma xenografts: tools for translational immunology. 2005 , 115, 1154-62	3
2121	Anti-tumor antibodies in ovarian cancer. 2005 , 54, 55-62	30
2120	Current concepts of tumor-infiltrating lymphocytes in human malignancies. 2005 , 67, 35-50	76
2119	Immune interactions at the maternal-fetal interface. 2005 , 68, 1-13	56
2118	Antagonism between MyD88- and TRIF-dependent signals in B7RP-1 up-regulation. 2005 , 35, 1918-27	16
2117	Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. 2005 , 104, 2084-91	149
2116	Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. 2005 , 54, 307-14	422
2115	The balance of immune responses: costimulation verse coinhibition. 2005 , 83, 193-202	59
2114	Immune Modulations. 2005 , 475-490	
2113	Immunity at the Maternal-Fetal Interface. 2005 , 1735-1745	1
2112	Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. 2005 , 10, 2856-60	49
2111	Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. 2005 , 174, 3408-15	157
2110	Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. 2005 , 11, 2947-53	630

2109	In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. 2005 , 201, 1531-41	129
2108	Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. 2005 , 33, 280-9	105
2107	Development of cancer vaccines to activate cytotoxic T lymphocytes. 2005 , 5, 555-63	10
2106	PD-1/PD-L pathway and autoimmunity. 2005 , 38, 353-7	70
2105	Strategies of antigen-specific T-cell-based immunotherapy for cancer. 2005 , 20, 491-501	9
2104	Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells. 2005 , 174, 898-906	51
2103	Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. 2005 , 174, 6648-56	127
2102	Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. 2005 , 25, 2537-46	134
2101	Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. 2005 , 11, 5708-17	89
2100	A critical role for the programmed death ligand 1 in fetomaternal tolerance. 2005 , 202, 231-7	316
2099	The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. 2005 , 306, 128-41	170
2098	Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. 2005 , 4, 1645-52	26
2097	Strategies of tumor immune evasion. 2005 , 19, 347-54	97
2096	Toll-like receptors on tumor cells facilitate evasion of immune surveillance. 2005 , 65, 5009-14	446
2095	The biology of human lymphoid malignancies revealed by gene expression profiling. 2005 , 87, 163-208	174
2094	Sinomenine inhibits B7-H1 and B7-DC expression on human renal tubular epithelial cells. 2005 , 5, 1446-57	19
2093	Expression of B7-H1 and B7-DC on the airway epithelium is enhanced by double-stranded RNA. 2005 , 330, 263-70	33
2092	PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. 2005 , 115, 184-91	66

2091	B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK). 2005 , 579, 6259-64	30
2090	B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. 2005 , 66, 10-4	42
2089	Immunologic aspect of ovarian cancer and p53 as tumor antigen. 2005 , 3, 34	28
2088	IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. 2005 , 40, 95-103	102
2087	Checkpoint blockade in cancer immunotherapy. 2006 , 90, 297-339	414
2086	Immunology of Pregnancy. 2006 ,	6
2085	The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. 2006 , 8, 190-8	439
2084	The human T cell response to melanoma antigens. 2006 , 92, 187-224	49
2083	Tumor Immunology and Immunotherapy. 2006 , 254-268	
2082	Cancer Drug Resistance. 2006 ,	17
2081	Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?. 2006 , 5, 773-81	9
2080	Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. 2006 , 177, 8844-50	158
2079	Mechanisms of immune evasion by tumors. 2006 , 90, 51-81	497
2078	Human T cell responses against melanoma. 2006 , 24, 175-208	530
2077	B7-H3 and B7-H4 expression in non-small-cell lung cancer. 2006 , 53, 143-51	249
2076	New battlefields for costimulation. 2006 , 203, 817-20	14
2075	Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. 2006 , 108, 19-24	397
2074	Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). 2006 , 580, 755-62	320

2073	PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. 2006 , 203, 2281-92	725
2072	Negative costimulatory molecules: the proximal of regulatory T cells?. 2006 , 67, 841-7	1
2071	Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. 2006 , 43, 763-71	232
2070	Triptolide inhibits B7-H1 expression on proinflammatory factor activated renal tubular epithelial cells by decreasing NF-kappaB transcription. 2006 , 43, 1088-98	24
2069	Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. 2006 , 12, 244-6	25
2068	The PD-1-PD-L pathway in immunological tolerance. 2006 , 27, 195-201	526
2067	Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1. 2006 , 47, 4607-13	11
2066	Manipulating Immunological Checkpoints to Maximize Antitumor Immunity. 2006 , 331-353	
2065	Manipulating T regulatory cells in cancer immunotherapy. 2006 , 1, 589-597	3
2064	Targeting tumor-related immunosuppression for cancer immunotherapy. 2006 , 6, 233-7	57
2063	Dendritic cell immunotherapy for melanoma. 2006 , 1, 87-102	2
2062	Immune suppression in the tumor microenvironment. 2006 , 29, 233-40	201
2061	Immunosuppressive Factors in Cancer. 2006 ,	
2060	The Tumor Microenvironment. 2006 , 285-301	
2059	Immune resistance orchestrated by the tumor microenvironment. 2006 , 213, 131-45	361
2058	Defeating T-cell fatigue in HIV. <i>Nature Medicine</i> , 2006 , 12, 1124-5	50.5 9
2057	Targeted cancer treatment: resisting arrest. <i>Nature Medicine</i> , 2006 , 12, 1125-6	50.5 4
2056	Prospects of RNA interference therapy for cancer. 2006 , 13, 464-77	279

2055	Current insights into the regulation of programmed cell death by NF-kappaB. 2006 , 25, 6800-16	342
2054	Effective cancer therapy through immunomodulation. 2006 , 57, 65-81	68
2053	Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy. 2006 , 195, 125-32	5
2052	Putting T cells to sleep: a new paradigm for immune evasion by persistent viruses. 2006 , 31, 497-501	2
2051	Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations. 2006 , 6, 2580-91	34
2050	Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency. 2006 , 34, 555-70	48
2049	The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. 2006 , 34, 888-94	38
2048	Escape from immune- and nonimmune-mediated tumor surveillance. 2006 , 16, 16-31	46
2047	Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. 2006 , 16, 3-15	336
2046	Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. 2006 , 42, 268-74	73
2045	Significance of B7-H1 overexpression in kidney cancer. 2006 , 5, 206-11	29
2044	Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. 2006 , 106, 2437-44	119
2043	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. 2006 , 119, 317-27	249
2042	HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. 2006 , 118, 2657-64	72
2041	High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals. 2006 , 79, 686-95	34
2040	Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. 2006 , 35, 327-57	32
2039	Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer. 2006 , 2, 261-272	5
2038	Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. 2006 , 203, 2223-7	333

2037	Trophoblast CD274 (B7-H1) is differentially expressed across gestation: influence of oxygen concentration. 2006 , 74, 352-8	46
2036	B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. 2006 , 177, 5928-35	174
2035	Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. 2006 , 12, 4794-803	90
2034	Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. 2006 , 66, 3381-5	696
2033	Modulation of immune response by B7 family molecules in tumor microenvironments. 2006 , 35, 395-418	11
2032	Development of antibodies and chimeric molecules for cancer immunotherapy. 2006 , 90, 83-131	36
2031	GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. 2006 , 66, 6816-25	66
2030	Expression of B7-H1 in inflammatory renal tubular epithelial cells. 2006 , 102, e81-92	35
2029	Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. 2006 , 66, 2442-50	110
2028	Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. 2006 , 12, 2359s-2365s	30
2027	Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. 2006 , 12, 5746-54	123
2026	B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. 2006 , 103, 10391-10396	252
2025	Roadmap to a better therapeutic tumor vaccine. 2006 , 25, 415-43	28
2024	B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. 2006 , 176, 6603-14	68
2023	Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. 2006 , 176, 1411-20	91
2022	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. 2006 , 203, 871-81	548
2021	Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. 2006 , 12, 2326s-2330s	76
2020	Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during <i>Helicobacter pylori</i> infection. 2006 , 176, 3000-9	131

2019	Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. 2006 , 177, 6081-90	45
2018	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. 2007 , 104, 3360-5	1081
2017	Prognostic biomarkers in renal cell carcinoma. 2007 , 7, 293-307	4
2016	Targeting costimulatory pathways for tumor immunotherapy. 2007 , 26, 161-96	21
2015	In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration. 2007 , 179, 2368-79	25
2014	IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. 2007 , 178, 3566-74	16
2013	Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. 2007 , 178, 5552-62	175
2012	Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. 2007 , 179, 2860-9	61
2011	PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. 2007 , 178, 2714-20	196
2010	CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. 2007 , 178, 5595-605	137
2009	PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. 2007 , 179, 5204-10	147
2008	Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. 2007 , 102, 302-12	60
2007	T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity. 2007 , 7, 55-70	20
2006	Costimulation, coinhibition and cancer. 2007 , 7, 15-30	79
2005	PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. 2007 , 22, 1527-36	42
2004	The ubiquitin E3 ligase Cbl-b in T cells tolerance and tumor immunity. 2007 , 6, 2478-85	14
2003	T-cell costimulation blockade in immunologic diseases: role of CD28 family members. 2007 , 3, 383-93	
2002	Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. 2007 , 19, 1223-34	189

2001	Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. 2007 , 13, 1749-56	88
2000	Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. 2007 , 67, 1832-41	69
1999	T-cell distribution and adhesion receptor expression in metastatic melanoma. 2007 , 13, 2549-56	59
1998	Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer. 2007 , 67, 11195-201	46
1997	B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. 2007 , 178, 6634-41	108
1996	PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. 2007 , 179, 5064-70	179
1995	Effects of specific immunotherapy on the B7 family of costimulatory molecules in allergic inflammation. 2007 , 178, 1931-7	14
1994	Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3. 2007 , 75, 158-67	37
1993	A link between PDL1 and T regulatory cells in fetomaternal tolerance. 2007 , 179, 5211-9	113
1992	Cellular and molecular mechanisms of tumor-induced T-cell tolerance. 2007 , 7, 41-53	26
1991	Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. 2007 , 67, 8900-5	254
1990	Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. 2007 , 13, 709s-715s	168
1989	Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. 2007 , 13, 2151-7	707
1988	12-O-tetradecanoyl phorbol 13-acetate induces the expression of B7-DC, -H1, -H2, and -H3 in K562 cells. 2007 ,	1
1987	Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN- γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. 2007 , 110, 296-304	482
1986	Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. 2007 , 110, 180-5	185
1985	Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody. 2007 ,	
1984	Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. 2007 , 83, 774-82	106

1983	The new B7s: playing a pivotal role in tumor immunity. 2007 , 30, 251-60	157
1982	GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. 2007 , 25 Suppl 2, B61-71	136
1981	Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. 2007 , 27, 111-22	1206
1980	Immune Escape Mechanisms of Renal Cell Carcinoma. 2007 , 6, 616-622	5
1979	Cancer stem cells and human malignant melanoma. 2008 , 21, 39-55	154
1978	Immunosuppressive strategies that are mediated by tumor cells. 2007 , 25, 267-96	1260
1977	General Principles of Tumor Immunotherapy. 2007 ,	2
1976	SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. 2007 , 110, 928-36	145
1975	Interactions with the Immune System. 2007 , 389-411	
1974	B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. 2007 , 67, 7893-900	198
1973	The B7 family and cancer therapy: costimulation and coinhibition. 2007 , 13, 5271-9	277
1972	The role of vascular cell adhesion molecule-1 in tumor immune evasion. 2007 , 67, 6003-6	82
1971	Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy. 2007 , 257-275	
1970	Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. 2007 , 9, 1-20	41
1969	T-Regulatory Cell Manipulation in Tumor Immunotherapy. 2007 , 189-204	
1968	Cancer Immunotherapy: Untapping the Potential of Costimulatory Molecules Beyond CTLA-4. 2007 , 243-268	
1967	Immune Escape: Immunosuppressive Networks. 2007 , 83-97	1
1966	Immune surveillance of tumors. 2007 , 117, 1137-46	942

1965	Immunotherapy and Cancer Therapeutics: Why Partner?. 2007 , 207-233	4
1964	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. 2017 , 6, 113-118	11
1963	Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor-Immune Escape. 2007 , 333-346	
1962	Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. 2007 , 121, 751-8	117
1961	Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma. 2007 , 121, 2585-90	75
1960	Vaccines to treat cancer--an old approach whose time has arrived. 2007 , 102, 291-300	9
1959	Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance. 2007 , 37, 2983-90	58
1958	PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. 2007 , 109, 1499-505	322
1957	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. <i>Nature Medicine</i> , 2007 , 13, 84-8	50.5 1020
1956	Immunostimulatory monoclonal antibodies for cancer therapy. 2007 , 7, 95-106	487
1955	Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. 2007 , 127, 1905-14	16
1954	PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. 2007 , 69, 19-27	62
1953	Porcine PD-L1: cloning, characterization, and implications during xenotransplantation. 2007 , 14, 236-42	27
1952	Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. 2007 , 57, 485-92	46
1951	Inhibitory costimulation and anti-tumor immunity. 2007 , 17, 288-98	23
1950	Immune suppression in renal cell carcinoma. 2007 , 17, 330-43	34
1949	Melanoma vaccines. 2007 , 34, 516-23	19
1948	Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. 2007 , 56, 88-94	44

1947	Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. 2007 , 56, 1173-82	345
1946	Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. 2007 , 56, 739-45	332
1945	Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. 2007 , 56, 1687-700	155
1944	Immunotherapeutic strategies employing RNA interference technology for the control of cancers. 2007 , 14, 15-29	15
1943	Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. 2008 , 57, 987-96	81
1942	Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation. 2008 , 1, 94-100	35
1941	Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?. 2008 , 393, 995-1003	14
1940	B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. 2008 , 134, 1021-7	97
1939	Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. 2008 , 113, 450-60	74
1938	Prognostic factors and selection for clinical studies of patients with kidney cancer. 2008 , 65, 235-62	60
1937	PD-1 and its ligands in tolerance and immunity. 2008 , 26, 677-704	3557
1936	Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. 2008 , 8, 5-15	34
1935	Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?. 2008 , 17, 383-94	42
1934	Immunotherapy of malignant brain tumors. 2008 , 222, 70-100	73
1933	Twelve immunotherapy drugs that could cure cancers. 2008 , 222, 357-68	255
1932	Signaling defects in anti-tumor T cells. 2008 , 222, 192-205	78
1931	The impact of T-cell immunity on ovarian cancer outcomes. 2008 , 222, 101-16	124
1930	The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. 2008 , 222, 277-86	101

1929	Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. 2008 , 224, 141-65	182
1928	Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanoma. 2008 , 128, 2750-2	7
1927	TLR signaling by tumor and immune cells: a double-edged sword. 2008 , 27, 218-24	280
1926	The Janus face of dendritic cells in cancer. 2008 , 27, 5920-31	72
1925	Modulation of the antitumor immune response by complement. 2008 , 9, 1225-35	494
1924	Inhibitory B7-family molecules in the tumour microenvironment. 2008 , 8, 467-77	1165
1923	T-cell death and cancer immune tolerance. 2008 , 15, 70-9	75
1922	Blockade of endogenous B7-H1 suppresses antibacterial protection after primary <i>Listeria monocytogenes</i> infection. 2008 , 123, 90-9	35
1921	Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. 2008 , 123, 538-46	114
1920	Human immunodeficiency virus (HIV-1) infection selectively downregulates PD-1 expression in infected cells and protects the cells from early apoptosis in vitro and in vivo. 2008 , 376, 140-53	21
1919	Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis. 2008 , 85, 174-88	36
1918	FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. 2008 , 8, 57	151
1917	Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. 2008 , 26, 5275-83	261
1916	Ovarian Cancer. 2008 ,	2
1915	Aptamers in immunotherapy. 2008 , 19, 443-50	40
1914	Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. 2008 , 45, 1470-6	190
1913	The complex role of B7 molecules in tumor immunology. 2008 , 14, 550-9	71
1912	Molecular markers for predicting prognosis of renal cell carcinoma. 2008 , 26, 113-24	33

1911	Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. 2008 , 268, 98-109	105
1910	Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. 2008 , 270, 337-41	34
1909	B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. 2008 , 365, 170-5	42
1908	Tumour immunity: effector response to tumour and role of the microenvironment. 2008 , 371, 771-83	415
1907	Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV. 2008 , 10, 711-9	13
1906	B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. 2008 , 179, 1954-9; discussion 1959-60	45
1905	TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells. 2008 , 26, 816-21	73
1904	Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. 2008 , 8, 951-68	52
1903	Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1. 2008 , 47, 1335-41	55
1902	Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. 2008 , 180, 130-7	49
1901	Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis. 2008 , 180, 7506-15	76
1900	Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy. 2008 , 180, 2981-8	21
1899	Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. 2008 , 181, 116-25	197
1898	Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). 2008 , 13 Suppl 4, 16-25	71
1897	Isopentenyl pyrophosphate-activated CD56+ $\gamma\delta$ T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. 2008 , 14, 4232-40	109
1896	Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. 2008 , 14, 5150-7	200
1895	Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. 2008 , 83, 755-64	38
1894	Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. 2008 , 14, 3044-51	563

1893	The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. 2008 , 181, 6738-46	358
1892	Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression. 2008 , 181, 6158-69	31
1891	Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. 2008 , 180, 4836-47	72
1890	Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. 2008 , 180, 335-49	70
1889	T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. 2008 , 14, 4800-8	204
1888	Inefficient Nef-mediated downmodulation of CD3 and MHC-I correlates with loss of CD4+T cells in natural SIV infection. 2008 , 4, e1000107	47
1887	Overcoming immune evasion in T cell therapy of cancer: lessons from animal models. 2008 , 8, 68-75	10
1886	Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. 2008 , 68, 5432-8	55
1885	Protective role of programmed death 1 ligand 1 (PD-L1) in nonobese diabetic mice: the paradox in transgenic models. 2008 , 57, 1861-9	56
1884	Melanoma. 2008 ,	1
1883	Expression and function of PDCD1 at the human maternal-fetal interface. 2008 , 79, 562-9	52
1882	Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell energy. 2008 , 181, 6707-10	112
1881	Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. 2008 , 181, 5842-6	64
1880	The programmed death-1 and interleukin-10 pathways play a down-modulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome. 2008 , 82, 2456-69	13
1879	Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. 2008 , 68, 292-300	56
1878	Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. 2008 , 7, 622-7	88
1877	PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. 2008 , 111, 3220-4	313
1876	B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. 2008 , 111, 3635-43	355

1875	The use of the inhibitory receptors for modulating the immune responses. 2008 , 14, 2643-50	17
1874	Expression of Ig-like transcript 4 inhibitory receptor in human non-small cell lung cancer. 2008 , 134, 783-788	33
1873	Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. 2008 , 3, 362-7	39
1872	. 2008 ,	0
1871	PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. 2008 , 49, 2518-25	94
1870	Renal cell carcinoma: biological features and rationale for molecular-targeted therapy. 2009 , 58, 1-11	14
1869	PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. 2009 , 50, 273-80	52
1868	TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. 2009 , 183, 3634-41	92
1867	Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. 2009 , 183, 4984-93	66
1866	Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. 2009 , 182, 3105-11	87
1865	Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. 2009 , 183, 1120-32	88
1864	Clinical importance of B7-H3 expression in human pancreatic cancer. 2009 , 101, 1709-16	125
1863	B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. 2009 , 11, 757-66	69
1862	Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. 2009 , 183, 5050-8	37
1861	Presence of membrane-bound TGF-beta1 and its regulation by IL-2-activated immune cell-derived IFN-gamma in head and neck squamous cell carcinoma cell lines. 2009 , 182, 6114-20	12
1860	Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies. 2009 , 183, 4077-87	22
1859	MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. 2009 , 182, 1325-33	163
1858	Renal Cell Carcinoma. 2009 ,	3

1857	Expression of immunosuppressive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. 2009 , 15, 2174-80	64
1856	Cellular immunotherapy for ovarian cancer. 2009 , 9, 677-88	25
1855	Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. 2009 , 35, 741-9	53
1854	Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression. 2009 , 182, 6744-52	12
1853	Inhibitors of B7-CD28 costimulation in urologic malignancies. 2009 , 1, 129-39	9
1852	Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. 2009 , 69, 8067-75	258
1851	Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. 2009 , 38, 624-38	42
1850	B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against <i>Leishmania donovani</i> infections. 2009 , 5, e1000431	124
1849	Melanomas reveal their nakedness: uncovered by interferon alfa. 2009 , 145, 587-8	
1848	Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. 2009 , 206, 1327-37	615
1847	Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. 2009 , 15, 1623-34	155
1846	Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. 2009 , 182, 5430-8	57
1845	PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. 2009 , 182, 5240-9	134
1844	Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. 2009 , 15, 6341-7	201
1843	Differentiation-induced post-transcriptional control of B7-H1 in human trophoblast cells. 2009 , 30, 48-55	15
1842	Immune escape mechanisms of intraocular tumors. 2009 , 28, 329-47	70
1841	Maternal PD-1 regulates accumulation of fetal antigen-specific CD8+ T cells in pregnancy. 2009 , 80, 12-21	60
1840	Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. 2009 , 9, 463	108

1839	Mechanistic insights into immunomodulation by hepatic stellate cells in mice: a critical role of interferon-gamma signaling. 2009 , 50, 1981-91	62
1838	Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. 2009 , 100, 500-4	87
1837	Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. 2009 , 135, 379-86	33
1836	Immunomodulation in the treatment of haematological malignancies. 2009 , 9, 81-92	6
1835	The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. 2009 , 26 Suppl 1, 3-12	14
1834	Betting on immunotherapy for melanoma. 2009 , 11, 397-404	17
1833	Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance. 2009 , 29, 77-9	29
1832	Methionine-enkephalin secreted by human colorectal cancer cells suppresses T lymphocytes. 2009 , 100, 497-502	23
1831	B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. 2009 , 100, 2093-100	110
1830	Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. 2009 , 157, 9-19	111
1829	PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. 2009 , 28, 306-12	132
1828	Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. 2009 , 229, 67-87	126
1827	Costimulatory and coinhibitory receptors in anti-tumor immunity. 2009 , 229, 126-44	202
1826	Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. 2009 , 74, 1-10	12
1825	Antitumor immunity and cancer stem cells. 2009 , 1176, 154-69	123
1824	Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. 2009 , 1174, 107-17	10
1823	B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. 2009 , 33, 948-57	36
1822	PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. 2009 , 206, 3015-29	1384

1821	The immune system and cancer. 2009 , 24, 369-76	53
1820	Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. 2009 , 276, 47-52	30
1819	Up-regulation of the expression of costimulatory molecule CD40 in hepatocytes by hepatitis B virus X antigen. 2009 , 384, 12-7	9
1818	T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangiomyomatosis. 2009 , 74, 1359-64	8
1817	Memory T cells need CD28 costimulation to remember. 2009 , 21, 69-77	84
1816	High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. 2009 , 40, 381-9	157
1815	Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. 2009 , 137, 682-90	129
1814	Emerging concepts in the immunopathogenesis of AIDS. 2009 , 60, 471-84	404
1813	Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. 2009 , 9, 1317-32	50
1812	Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. 2009 , 58, 520-9	191
1811	Dendritic cells in the skin—potential use for melanoma treatment. 2009 , 22, 30-41	10
1810	Regulaci3n inmune durante la coinfecci3n por el virus de la inmunodeficiencia humana y el Mycobacterium tuberculosis. 2009 , 13, 268-282	
1809	Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. 2009 , 32, 585-92	64
1808	Molecular Mechanisms of Immune Suppressive Microenvironment in the Cornea. 2009 , 28, S58-S64	1
1807	Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. 2009 , 20, 1597-602	34
1806	Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. 2009 , 114, 1537-44	1123
1805	PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. 2009 , 114, 1545-52	297
1804	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. 2009 , 114, 2149-58	162

1803	Prevalence of antitumor antibodies in laying hen model of human ovarian cancer. 2009 , 19, 500-7	23
1802	Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting. 2009 , 9, 911-27	15
1801	Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. 2010 , 33, 956-64	133
1800	B7-H1 expression in vestibular schwannomas. 2010 , 31, 991-7	24
1799	B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. 2010 , 252, 1044-51	96
1798	Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. 2010 , 116, 1124-31	150
1797	B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. 2010 , 116, 1291-8	253
1796	Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. 2010 , 207, 2187-94	1289
1795	Generation and characterization of four novel monoclonal antibodies against human programmed death-1 molecule. 2010 , 29, 153-60	6
1794	RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. 2010 , 59, 1173-83	44
1793	In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. 2010 , 59, 1839-49	121
1792	Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. 2010 , 34, 1059-65	91
1791	Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients. 2010 , 136, 1445-52	32
1790	Structural immunology of costimulatory and coinhibitory molecules. 2010 , 53, 183-9	5
1789	Immune evasive mechanisms contributing to persistent Leishmania donovani infection. 2010 , 47, 14-24	24
1788	Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. 2010 , 37, 430-9	230
1787	Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. 2010 , 225, 22-33	65
1786	Immune evasion by neocartilage-derived chondrocytes: Implications for biologic repair of joint articular cartilage. 2010 , 4, 57-68	94

1785	PD-1, gender, and autoimmunity. 2010 , 9, 583-7	64
1784	Overexpression of programmed death-1 ligand-1 on NIT cells lead to negative regulation of allogeneic lymphocyte activation. 2010 , 263, 122-8	1
1783	PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft. 2010 , 10, 40-6	80
1782	Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. 2010 , 116, 1757-66	511
1781	Tumor progression by immune evasion in melanoma: role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction. 2010 , 116, 1623-5	12
1780	Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. 2010 , 32, 946-58	42
1779	Toll-like receptors: expression and involvement in multiple myeloma. 2010 , 34, 1545-50	26
1778	The stromal gene encoding the CD274 antigen as a genetic modifier controlling survival of mice with β radiation-induced T-cell lymphoblastic lymphomas. 2010 , 29, 5265-73	7
1777	Harnessing the immune response to treat cancer. 2010 , 29, 6301-13	65
1776	Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. 2010 , 7, 389-95	193
1775	Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter. 2010 , 11, 55-66	15
1774	Expression and function of B7 family molecules in hematologic malignancies. 2010 , 77, 45-7	
1773	CD4 T-cell suppression by cells from <i>Toxoplasma gondii</i> -infected retinas is mediated by surface protein PD-L1. 2010 , 78, 3484-92	16
1772	T-lymphocyte subpopulations and B7-H1/PD-1 expression in nasal polyposis. 2010 , 38, 593-601	3
1771	<i>Cryptosporidium parvum</i> induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513. 2010 , 201, 160-9	56
1770	<i>Toxoplasma gondii</i> activates hypoxia-inducible factor (HIF) by stabilizing the HIF-1alpha subunit via type I activin-like receptor kinase receptor signaling. 2010 , 285, 26852-26860	46
1769	Glioma-associated cancer-initiating cells induce immunosuppression. 2010 , 16, 461-73	196
1768	Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. 2010 , 9, 67-78	205

1767	DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. 2010 , 70, 5778-87	50
1766	Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. 2010 , 28, 3167-75	2163
1765	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. 2010 , 12, 351-65	163
1764	Memory T Cells. 2010 ,	1
1763	Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. 2010 , 185, 5082-92	57
1762	Keratinocyte-associated B7-H1 directly regulates cutaneous effector CD8+ T cell responses. 2010 , 184, 4918-25	30
1761	Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. 2011 , 344, 245-67	36
1760	Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. 2010 , 184, 3442-9	121
1759	Drug Management of Prostate Cancer. 2010 ,	3
1758	Tumor infiltrating regulatory T cells: tractable targets for immunotherapy. 2010 , 29, 461-84	5
1757	Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. 2010 , 16, 255-67	25
1756	Vaccines against human carcinomas: strategies to improve antitumor immune responses. 2010 , 2010, 380697	35
1755	Stimulation of B7-H1 in hepatocarcinoma cells by hepatitis B virus X antigen. 2010 , 39, 754-69	4
1754	Functional significance of B7-H1 expressed by human uveal melanoma cells. 2011 , 4, 163-7	15
1753	Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. 2010 , 23, 1393-403	122
1752	T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. 2010 , 18, 2006-17	59
1751	Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. 2010 , 2, 367-79	20
1750	Microglia and central nervous system immunity. 2010 , 21, 43-51	42

1749	Biologic principles of immunotherapy for malignant gliomas. 2010 , 21, 1-16	12
1748	Cancer-associated myeloproliferation: old association, new therapeutic target. 2010 , 85, 656-63	64
1747	Tumour escape mechanisms and their therapeutic implications in combination tumour therapy. 2010 , 34, 553-63	18
1746	The role of microglia in central nervous system immunity and glioma immunology. 2010 , 17, 6-10	247
1745	Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. 2010 , 17, 1543-7	28
1744	Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. 2010 , 12, R48	151
1743	Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. 2010 , 70, 9581-90	80
1742	Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?. 2011 , 11, 441-5	22
1741	Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. 2011 , 3, 1235-51	39
1740	Cancer Immunology and Immunotherapy. 2011 ,	1
1739	Sarcoma immunotherapy. 2011 , 3, 4139-50	3
1738	Immunotherapy for renal cell carcinoma. 2011 , 25, 793-812	22
1737	Emerging Therapeutic Targets in Ovarian Cancer. 2011 ,	1
1736	Evasive strategies in rabies virus infection. 2011 , 79, 33-53	73
1735	Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. 2011 , 56, 231-8	155
1734	B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis. 2011 , 216, 1302-10	59
1733	Emerging Tim-3 functions in antimicrobial and tumor immunity. 2011 , 32, 345-9	184
1732	T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. 2011 , 17, 47-55	36

1731	Tolerance induction by allogeneic hematopoietic stem cells. 2011 , 9, 87-8	3
1730	Intracellular events and cell fate in filovirus infection. 2011 , 3, 1501-31	60
1729	Cellular Immunotherapy for Malignant Brain Tumors. 2011 ,	
1728	Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. 2011 , 6, e23621	123
1727	Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. 2011 , 6, e26125	112
1726	Tumor immune escape mechanisms that operate during metastasis. 2011 , 12, 1923-36	17
1725	Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. 2011 , 17, 372-8	24
1724	HIV-1 infection and induction of interferon alpha in plasmacytoid dendritic cells. 2011 , 6, 373-8	23
1723	Molecular markers of response to treatment for melanoma. 2011 , 17, 127-33	16
1722	PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. 2011 , 34, 409-18	232
1721	Advances in dendritic cell-based vaccines for HIV. 2011 , 18, 3987-94	5
1720	Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway. 2011 , 23, 295-9	33
1719	Interferon β limits the effectiveness of melanoma peptide vaccines. 2011 , 117, 135-44	52
1718	S β ary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. 2011 , 117, 3382-90	28
1717	Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis. 2011 , 38, 1219-26	40
1716	Role of PD-L1 and PD-L2 in allergic diseases and asthma. 2011 , 66, 155-62	83
1715	Targeting glioma stem cells: a novel framework for brain tumors. 2011 , 102, 1958-66	80
1714	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. 2011 , 241, 104-18	185

1713	Timeline: a decade of advances in immunotherapy. <i>Nature Medicine</i> , 2011 , 17, 296	50.5	3
1712	The role of the PD-1 pathway in autoimmunity and peripheral tolerance. 2011 , 1217, 45-59		219
1711	Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. 2011 , 47, 1148-53		160
1710	Potential strategies of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat. 2011 , 16, 733-40		16
1709	Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. 2011 , 60, 644-61		224
1708	Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma. 2011 , 91, 1025-31		41
1707	Natural innate and adaptive immunity to cancer. 2011 , 29, 235-71		1353
1706	Cancer immunotherapy comes of age. 2011 , 29, 4828-36		336
1705	PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. 2011 , 129, 195-201		59
1704	Improving cancer immunotherapy by targeting tumor-induced immune suppression. 2011 , 30, 125-40		115
1703	Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. 2011 , 30, 141-51		41
1702	Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma. 2011 , 28, 661-74		19
1701	Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. 2011 , 60, 123-31		13
1700	Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. 2011 , 60, 869-82		19
1699	Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction. 2011 , 60, 1109-18		36
1698	Combination of targeted therapy and immunotherapy in melanoma. 2011 , 60, 1359-71		36
1697	Dual biological effects of the cytokines interleukin-10 and interferon- γ . 2011 , 60, 1529-41		101
1696	Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. 2011 , 60, 47-53		43

1695	T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. 2011 , 50, 269-75	54
1694	High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. 2011 , 28, 682-8	455
1693	Immunosuppressive tumor microenvironment in cervical cancer patients. 2011 , 4, 361-75	77
1692	A fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumors. 2011 , 10, 105	8
1691	Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. 2011 , 41, 2217-28	59
1690	Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. 2011 , 41, 2314-22	69
1689	Overall survival and PD-L1 expression in metastasized malignant melanoma. 2011 , 117, 2192-201	178
1688	PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. 2011 , 128, 887-96	299
1687	Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. 2011 , 129, 2651-61	80
1686	B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. 2011 , 71, 1235-43	74
1685	Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer. 2011 , 3, 805-7	3
1684	An essential role for programmed death-1 in the control of autoimmunity: implications for the future of hematopoietic stem cell transplantation. 2011 , 7, 929-32	2
1683	Therapeutic targeting of B7-H1 in breast cancer. 2011 , 15, 1211-25	34
1682	Ambivalent role of the innate immune response in rabies virus pathogenesis. 2011 , 85, 6657-68	39
1681	B7-h1 expressed by activated CD8 T cells is essential for their survival. 2011 , 187, 5606-14	48
1680	T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. 2011 , 17, 5736-47	32
1679	Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. 2011 , 17, 1915-23	235
1678	Targeting the tumor microenvironment by immunotherapy: part 2. 2011 , 3, 1385-408	5

1677	VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. 2011 , 208, 577-92	388
1676	Phenotype, function, and gene expression profiles of programmed death-1 (hi) CD8 T cells in healthy human adults. 2011 , 186, 4200-12	168
1675	Intracellular estrogen receptor-binding fragment-associated antigen 9 exerts in vivo tumor-promoting effects via its coiled-coil region. 2011 , 39, 41-9	2
1674	Genetic and modifying factors that determine the risk of brain tumors. 2011 , 11, 8-30	10
1673	Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction. 2011 , 187, 2291-301	21
1672	Human PD-L1-overexpressing porcine vascular endothelial cells induce functionally suppressive human CD4+CD25hiFoxp3+ Treg cells. 2011 , 90, 77-86	15
1671	Cancer immunoediting of the NK group 2D ligand H60a. 2011 , 187, 3538-45	23
1670	Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. 2011 , 186, 6822-9	60
1669	Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. 2011 , 17, 4232-44	262
1668	Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. 2011 , 3, 2904-54	10
1667	Differential regulation of T and B lymphocytes by PD-1 and SOCS-1 signaling in hepatitis C virus-associated non-Hodgkin's lymphoma. 2011 , 40, 243-64	16
1666	Immune therapy for ovarian cancer: promise and pitfalls. 2011 , 30, 102-19	19
1665	Tumor evasion from T cell surveillance. 2011 , 2011, 918471	105
1664	Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis. 2011 , 71, 4737-41	29
1663	Peritoneal immune system in patients with advanced epithelial ovarian cancer. 2011 , 30, 87-101	11
1662	Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease. 2012 , 188, 724-34	24
1661	Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. 2012 , 2012, 818214	20
1660	Programmed death ligand 2 in cancer-induced immune suppression. 2012 , 2012, 656340	231

1659	Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. 2012 , 2012, 741741	53
1658	Role of T lymphocytes in tumor response to radiotherapy. 2012 , 2, 95	112
1657	Targeting costimulatory molecules to improve antitumor immunity. 2012 , 2012, 926321	53
1656	Regional lymphatic immunity in melanoma. 2012 , 22, 9-18	15
1655	T-cell inhibitors: a bench-to-bedside review. 2012 , 23, 195-202	3
1654	Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. 2012 , 4, 127ra37	1562
1653	Anti- α TCR antibody-expanded α T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. 2012 , 9, 34-44	44
1652	Prophylactic vaccine approach for colon and pancreatic cancers: present and future. 2012 , 19, 3664-78	3
1651	B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. 2012 , 1, 1061-1073	33
1650	The PD-1/PD-L1 pathway in human pathology. 2012 , 12, 259-67	50
1649	Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism and susceptibility to pancreatic cancer. 2012 , 31, 683-7	17
1648	Effects of interferon- α transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors. 2012 , 19, 637-43	15
1647	Advances in Cancer Stem Cell Biology. 2012 ,	2
1646	Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. 2012 , 189, 4674-83	172
1645	Targeting PD-1/PD-L1 interactions for cancer immunotherapy. 2012 , 1, 1223-1225	248
1644	Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism?. 2012 , 3, 148	45
1643	The confluence of radiotherapy and immunotherapy. 2012 , 2, 143	46
1642	Lessons from cancer immunoediting in cutaneous melanoma. 2012 , 2012, 192719	17

1641	Immunotherapy for prostate cancer enters its golden age. 2012 , 6, 263-73	6
1640	Differential Regulation of the Immune Response in the Spleen and Liver of Mice Infected with <i>Leishmania donovani</i> . 2012 , 2012, 639304	38
1639	Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. 2012 , 2012, 890178	41
1638	Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. 2012 , 2012, 160724	37
1637	B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. 2012 , 189, 181-90	30
1636	IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells. 2012 , 188, 5227-37	77
1635	Synthetic small peptides acting on B7H1 enhance apoptosis in pancreatic cancer cells. 2012 , 6, 553-7	4
1634	Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study. 2012 , 98, 751-755	134
1633	Mechanisms of indirect acute lung injury: a novel role for the coinhibitory receptor, programmed death-1. 2012 , 255, 158-64	39
1632	PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. 2012 , 35, 169-78	203
1631	Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. 2012 , 34, 126-8	87
1630	Pancreatic ductal adenocarcinoma: a review of immunologic aspects. 2012 , 60, 643-63	41
1629	Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. 2012 , 18, 6580-7	415
1628	Immunology beats cancer: a blueprint for successful translation. 2012 , 13, 1129-32	130
1627	Immunotherapy for glioma: promises and challenges. 2012 , 23, 357-70	26
1626	The HIF-1 β hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. 2012 , 2, 608-23	124
1625	The expression, function, and clinical relevance of B7 family members in cancer. 2012 , 61, 1327-41	62
1624	Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. 2011 , 3, 1	12

1623	Znaczenie receptora programowanej śmierci 1 oraz jego liganda w układzie immunologicznym oraz nowotworach. 2012 , 43, 132-145	7
1622	Immunotherapy earns its spot in the ranks of cancer therapy. 2012 , 209, 201-9	108
1621	Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. 2012 , 29, 729-36	30
1620	PD-1 blockade: promoting endogenous anti-tumor immunity. 2012 , 12, 1279-82	11
1619	A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease. 2012 , 33, 624.e11-22	27
1618	Role of PD-L1/PD-1 in the immune response to respiratory viral infections. 2012 , 14, 495-9	14
1617	Interferon-Induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. 2012 , 217, 385-93	116
1616	Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients. 2012 , 217, 669-75	44
1615	Costimulatory molecule expression on human uveal melanoma cells: functional analysis of CD40 and B7-H1. 2012 , 96, 98-106	16
1614	Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. 2012 , 24, 207-12	979
1613	Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. 2012 , 56, 1342-51	305
1612	Mechanisms of immune evasion by gliomas. 2012 , 746, 53-76	76
1611	Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. 2012 , 83, 432-43	24
1610	Melanoma in immunosuppressed patients. 2012 , 87, 991-1003	79
1609	Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. 2012 , 53, 2015-23	33
1608	Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells. 2012 , 92, 673-82	53
1607	Control of Innate and Adaptive Immune Responses during Infectious Diseases. 2012 ,	1
1606	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. 2012 , 366, 2443-54	8684

1605	Glioma. 2012,	2
1604	Innate Immune Regulation and Cancer Immunotherapy. 2012,	3
1603	Protocadherin-18 is a novel differentiation marker and an inhibitory signaling receptor for CD8+ effector memory T cells. 2012, 7, e36101	14
1602	Neisseria gonorrhoeae suppresses dendritic cell-induced, antigen-dependent CD4 T cell proliferation. 2012, 7, e41260	32
1601	Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. 2012, 7, e45272	134
1600	Immune sculpting of norepinephrine on MHC-I, B7-1, IDO and B7-H1 expression and regulation of proliferation and invasion in pancreatic carcinoma cells. 2012, 7, e45491	18
1599	Apoptosis - an Ubiquitous T cell Immunomodulator. 2011, S3, 2	9
1598	Modulation of normal and malignant plasma cells function by toll-like receptors. 2012, 4, 2289-301	
1597	Targeting Immune Checkpoints. 2012, 18, 153-159	28
1596	Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. 2012, 7, 93-103	37
1595	MELANOMA-ASSOCIATED SUPPRESSION OF THE DENDRITIC CELL LINES DC2.4 AND JAWSII. 2012, 8, 179-190	7
1594	The blockade of immune checkpoints in cancer immunotherapy. 2012, 12, 252-64	8091
1593	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. 2012, 366, 2455-65	5527
1592	Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8+ T cells. 2012, 42, 662-71	13
1591	PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease. 2012, 130, 2327-36	27
1590	Tumor-induced changes in the phenotype of blood-derived and tumor-associated T cells of early stage breast cancer patients. 2012, 131, 1611-20	40
1589	Basic concepts in glioma immunology. 2012, 746, 42-52	39
1588	Role of PD-1 in HIV pathogenesis and as target for therapy. 2012, 9, 81-90	99

1587	Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. 2012 , 61, 917-26	115
1586	The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. 2012 , 61, 1101-11	33
1585	Prostate cancer and inflammation: the evidence. 2012 , 60, 199-215	400
1584	Advances in the treatment of metastatic melanoma: new immunomodulatory agents. 2012 , 39, 192-203	10
1583	Dendritic/tumor fusion cells as cancer vaccines. 2012 , 39, 287-95	30
1582	Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. 2012 , 51, 263-72	132
1581	Immunotherapy for metastatic melanoma. 2012 , 113, 725-34	10
1580	A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. 2012 , 33, 480-4	79
1579	Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development. 2012 , 32, 1197-219	14
1578	The clinical implications of antitumor immunity in head and neck cancer. 2012 , 122, 144-57	45
1577	B7-h1 and a mathematical model for cytotoxic T cell and tumor cell interaction. 2012 , 74, 91-102	7
1576	Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. 2013 , 11, 147	44
1575	Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast. 2013 , 34, 1053-9	21
1574	Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. 2013 , 15, 98-104	35
1573	B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. 2013 , 7, 113-21	103
1572	Immune exhaustion and immune senescence: two distinct pathways for HBV vaccine failure during HCV and/or HIV infection. 2013 , 61, 193-201	35
1571	Expression and significance of B7-H1 in peripheral blood dendritic cells from patients with bladder cancer. 2013 , 12, 290-292	
1570	Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases. 2013 , 62, 778-85	49

1569	Can exercise-related improvements in immunity influence cancer prevention and prognosis in the elderly?. 2013 , 76, 51-6	53
1568	Targeting the immune system in the treatment of non-small-cell lung cancer. 2013 , 14, 580-94	11
1567	Deciphering and reversing tumor immune suppression. 2013 , 39, 61-73	392
1566	Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. 2013 , 25, 182-90	39
1565	Individualising treatment choices in a crowded treatment algorithm. 2013 , 11, 160-8	2
1564	Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. 2013 , 73, 3591-603	475
1563	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. 2013 , 110, 20212-7	1041
1562	A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. 2013 , 14, 1212-8	611
1561	PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. 2013 , 19, 3462-73	601
1560	Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. 2013 , 190, 4899-909	144
1559	Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. 2013 , 191, 4121-9	70
1558	Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?. 2013 , 13, 1399-408	9
1557	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. 2013 , 19, 5300-9	485
1556	The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. 2013 , 6, 74	176
1555	Immune evasion in acute myeloid leukemia: current concepts and future directions. 2013 , 1,	54
1554	Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. 2013 , 20, 3106-11	39
1553	Immunotherapy for the management of advanced melanoma: the next steps. 2013 , 14, 261-72	14
1552	Cancer immunotherapy: are we there yet?. 2013 , 2, 33	20

1551	Cancer immunotherapy: current status and future directions. 2013 , 22, 765-83	18
1550	Systems Biology of Tumor Dormancy. 2013 ,	6
1549	Immunology. 2013 , 387-408	4
1548	Immune Escape. 2013 , 149-164	1
1547	Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. 2013 , 9, 391-397	9
1546	T-cell tolerance in cancer. 2013 , 5, 513-531	33
1545	Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. 2013 , 73, 1733-41	564
1544	Tumor dormancy: long-term survival in a hostile environment. 2013 , 734, 181-200	10
1543	Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients. 2013 , 16, 473-9	26
1542	Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. 2013 , 20, 103-10	55
1541	Immune Co-signaling to Treat Cancer. 2013 , 211-280	1
1540	Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. 2013 , 36, 110-20	24
1539	Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. 2013 , 151, 71-5	42
1538	Immunotherapy of melanoma. 2013 , 11, 97-105	39
1537	[Immunological analogies between ovarian cancer and pregnancy]. 2013 , 42, 217-26	
1536	Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. 2013 , 31, 639-46	26
1535	Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. 2013 , 31, 2449-56	12
1534	Advances in targeting cell surface signalling molecules for immune modulation. 2013 , 12, 130-46	192

1533	Adaptive resistance: a tumor strategy to evade immune attack. 2013 , 43, 576-9	15
1532	The transcription factor NFAT exhibits signal memory during serial T cell interactions with antigen-presenting cells. 2013 , 38, 237-49	110
1531	Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. 2013 , 21, 688-95	44
1530	Other signalization targets. 2013 , 8, 69-77	5
1529	Tumor dormancy and cancer stem cells: two sides of the same coin?. 2013 , 734, 145-79	88
1528	Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. 2013 , 121, 3619-30	41
1527	Emerging targeted agents in metastatic breast cancer. 2013 , 10, 191-210	138
1526	Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. 2013 , 25, 268-76	275
1525	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. 2013 , 13, 847-61	96
1524	Vaccines against advanced melanoma. 2013 , 31, 179-90	18
1523	A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. 2013 , 132, 641-8	116
1522	At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. 2013 , 94, 25-39	266
1521	Antibody-based therapy in colorectal cancer. 2013 , 5, 533-45	21
1520	Melanoma immunotherapy: historical precedents, recent successes and future prospects. 2013 , 5, 169-82	24
1519	Immune privilege of stem cells. 2013 , 1029, 1-16	12
1518	The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. 2013 , 139, 667-76	236
1517	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. 2013 , 94, 41-53	232
1516	Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC). 2013 , 94, 1201-6	8

1515	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. 2013 , 76, 233-47	31
1514	Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. 2013 , 94, 963-70	35
1513	Targeted therapy for non-small-cell lung cancer: past, present and future. 2013 , 13, 745-58	68
1512	Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?. 2013 , 40, 347-60	13
1511	Expression Profiling of Hepatocellular Carcinoma. 2013 , 163-184	
1510	Cell Death Signaling in Cancer Biology and Treatment. 2013 ,	1
1509	Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. 2013 , 336, 253-9	61
1508	Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. 2013 , 62, 1369-80	23
1507	The Tumor Immunoenvironment. 2013 ,	3
1506	MHC Class I Antigens In Malignant Cells. 2013 ,	3
1505	Manipulating the PD-1 pathway to improve immunity. 2013 , 25, 381-8	75
1504	PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. 2013 , 33, 14231-45	98
1503	Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. 2013 , 19, 997-1008	144
1502	Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. 2013 , 31, 4311-8	447
1501	Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. 2013 , 191, 2829-36	50
1500	Lenalidomide enhances anti-myeloma cellular immunity. 2013 , 62, 39-49	123
1499	Koch Institute Symposium on Cancer Immunology and Immunotherapy. 2013 , 1, 217-222	0
1498	Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. 2013 , 98, 1458-66	42

1497	Vaccine-based immunotherapy for glioblastoma. 2013 , 2, 331-49	8
1496	Differentiated thyroid carcinomas and their B7H1 shield. 2013 , 9, 1417-9	8
1495	Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways. 2013 , 13, 352-357	2
1494	Combination immune therapies to enhance anti-tumor responses by NK cells. 2013 , 4, 481	57
1493	Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. 2013 , 3, 63	66
1492	Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics. 2013 , 19, 348-52	16
1491	Alerting the immune system via stromal cells is central to the prevention of tumor growth. 2013 , 2, e27091	2
1490	T cells and costimulation in cancer. 2013 , 19, 473-82	17
1489	Endogenous tumor-reactive CD8 T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. 2013 , 2, e23972	30
1488	Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. 2013 , 36, 442-50	20
1487	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. 2013 , 19, 1021-34	381
1486	PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. 2013 , 19, 1363-74	151
1485	Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils. 2013 , 94, 813-23	29
1484	HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. 2013 , 73, 1764-76	62
1483	What lies within: novel strategies in immunotherapy for non-small cell lung cancer. 2013 , 18, 1203-13	30
1482	Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. 2013 , 169, R153-64	82
1481	Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. 2013 , 5, 105-18	31
1480	PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. 2013 , 123, 2604-15	174

1479	The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence. 2013 , 1, 33-47	5
1478	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response. 2013 , 19, 5542	90
1477	Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer. 2013 , 4, 382	9
1476	Evolving pharmacotherapies for the treatment of metastatic melanoma. 2013 , 7, 137-49	6
1475	Immunotherapy in advanced cutaneous melanoma patients. 2013 , 5, 429-433	
1474	Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. 2013 , 19, 3165-75	286
1473	PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. 2013 , 1, 54-63	277
1472	c-Rel in GVHD biology: a missing link. 2013 , 43, 2255-8	
1471	Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era. 2013 , 90, 286-90	21
1470	Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. 2013 , 107, 517-22	64
1469	Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. 2013 , 2, e25961	143
1468	Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. 2013 , 1, 378-85	31
1467	Biological Niches Characterizing Pathological Lesions. 2013 , 5, 139-173	1
1466	The delicate balance of melanoma immunotherapy. 2013 , 2, e5	21
1465	Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. 2013 , 27, 464-72	185
1464	Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. 2013 , 108, 1560-5	114
1463	Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model. 2013 , 190, 6651-61	22
1462	The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells. 2013 , 2, e23991	42

1461	Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma. 2013 , 5, 90-96	22
1460	Hepatic stellate cells promote immunotolerance following orthotopic liver transplantation in rats via induction of T cell apoptosis and regulation of Th2/Th3-like cell cytokine production. 2013 , 5, 165-169	14
1459	gene expression in Japanese lung cancer patients. 2013 , 1, 93-96	10
1458	The role of B7 family molecules in hematologic malignancy. 2013 , 121, 734-44	132
1457	Melanoma mutagenesis and aberrant cell signaling. 2013 , 20, 261-81	20
1456	Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. 2013 , 8, 587-98	51
1455	Current Advances in Therapy for Metastatic Melanoma. 2013 , 9, 8-23	
1454	B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice. 2013 , 30, 2442-8	8
1453	Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway. 2013 , 96, 17-24	42
1452	Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. 2013 ,	23
1451	Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. 2013 , 15, R75	44
1450	Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. 2013 , 2, 73-90	23
1449	A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. 2013 , 8, e63818	181
1448	PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. 2013 , 8, e65821	173
1447	B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. 2013 , 8, e76012	116
1446	Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice. 2013 , 8, e79874	28
1445	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. 2013 , 4, 417	53
1444	Interferon- γ triggers hepatic stellate cell-mediated immune regulation through MEK/ERK signaling pathway. 2013 , 2013, 389807	16

1443	Emerging Co-signaling Networks in T Cell Immune Regulation. 2013 , 13, 184-93	40
1442	Immune privilege as new therapeutic strategies for success of corneal transplantation. 2013 , 33, 274-282	0
1441	Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. 2014 , 1	1
1440	Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. 2014 , 7, 567-73	172
1439	PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. 2014 , 9, e89350	135
1438	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. 2014 , 7, 357-65	49
1437	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. 2014 , 5, 165	99
1436	Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. 2014 , 4, 386-401	12
1435	PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. 2014 , 5, 166-72	116
1434	The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. 2014 , 14, 265-76	65
1433	RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. 2014 , 1,	
1432	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. 2014 ,	3
1431	Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential. 2014 , 3, e954467	13
1430	PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. 2014 , 6, 737-53	14
1429	Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy. 2014 , 3, e954868	8
1428	Im Fokus Das Nierenzellkarzinom. 2014 , 17, 23-26	
1427	Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. 2014 , 74, 4042-52	94
1426	Hodgkin Lymphoma and the Microenvironment. 2014 , 1701-1712	

1425	Successes and limitations of targeted cancer therapy in melanoma. 2014 , 41, 78-88	3
1424	CD271 on melanoma cell is an IFN- γ -inducible immunosuppressive factor that mediates downregulation of melanoma antigens. 2014 , 134, 1369-1377	41
1423	Overcoming tumor-mediated immunosuppression. 2014 , 6, 973-88	28
1422	NKT cell networks in the regulation of tumor immunity. 2014 , 5, 543	81
1421	Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?. 2014 , 6, 1180-94	8
1420	Vaccines against Cancer. 2014 ,	
1419	Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. 2014 , 2014, 639058	18
1418	Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. 2014 , 10, e1003409	35
1417	BRAF and beyond: Tailoring strategies for the individual melanoma patient. 2014 , 13, 1	13
1416	Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma. 2014 , 2014, 396064	20
1415	Combinations of immunotherapy and radiation in cancer therapy. 2014 , 4, 325	164
1414	Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. 2014 , 3, 175-190	1
1413	New treatments for metastatic melanoma. 2014 , 186, 754-60	9
1412	Targeting CD8+ T-cell tolerance for cancer immunotherapy. 2014 , 6, 833-52	37
1411	[Recurrence of upper aerodigestive tract tumors]. 2014 , 101, 511-20	3
1410	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. 2014 , 28, 2367-75	239
1409	Significant involvement of herpesvirus entry mediator in human esophageal squamous cell carcinoma. 2014 , 120, 808-17	23
1408	Immunological in vivo effects of B7-H1 deficiency. 2014 , 162, 273-86	3

1407	Advances in Tumor Immunology and Immunotherapy. 2014,	0
1406	TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. 2014, 6, 1294-311	73
1405	Why is melanoma so metastatic?. 2014, 27, 19-36	69
1404	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. 2014, 515, 563-7	3354
1403	Negative role of inducible PD-1 on survival of activated dendritic cells. 2014, 95, 621-9	30
1402	Neglected Tropical Diseases and Conditions of the Nervous System. 2014,	3
1401	Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. 2014, 120, 624-32	39
1400	PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. 2014, 2, 1132-41	33
1399	Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. 2014, 134, 2772-7	47
1398	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. 2014, 5, 5241	573
1397	Evolving role of tumor antigens for future melanoma therapies. 2014, 10, 1457-68	11
1396	Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. 2014, 28, 513-26	7
1395	The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism. 2014, 31, 268	19
1394	The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. 2014, 26, 204-14	57
1393	B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. 2014, 9, 1036-1040	177
1392	Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. 2014, 20, 256-61	96
1391	Tumor-stroma crosstalk: targeting stroma in breast cancer. 2014, 26, 551-5	37
1390	Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. 2014, 20, 272-80	14

1389	Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. 2014 , 6, 237ra67	432
1388	Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy. 2014 , 5, 74	34
1387	Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. 2014 , 20, 1223-34	71
1386	gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer. 2014 , 2, 1035-1042	18
1385	Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro. 2014 , 7, 1389-96	13
1384	From the guest editor: Tumor site immune modulation therapy. 2014 , 20, 254-5	6
1383	Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis. 2014 , 37, 116-21	45
1382	New drug targets in metastatic melanoma. 2014 , 232, 134-41	47
1381	Change of Address. 2014 , 70, 956	
1380	Monocyte-derived cells of the brain and malignant gliomas: the double face of Janus. 2014 , 82, 1171-86	21
1379	The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. 2014 , 31, 111-34	14
1378	Immunotherapy: it takes a village. 2014 , 344, 149	12
1377	Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. 2014 , 63, 215-24	81
1376	Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. 2014 , 12, 36	122
1375	Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. 2014 , 89, 140-65	122
1374	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. 2014 , 27, 89-97	90
1373	Hair follicle mesenchyme-associated PD-L1 regulates T-cell activation induced apoptosis: a potential mechanism of immune privilege. 2014 , 134, 736-745	31
1372	Adenoviral vector-mediated gene therapy for gliomas: coming of age. 2014 , 14, 1241-57	35

1371	A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. 2014 , 2, 610-5	29
1370	Programmed death ligand-1 expression in non-small cell lung cancer. 2014 , 94, 107-16	591
1369	Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. 2014 , 6, 459-75	76
1368	Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. 2014 , 10, 41-62	77
1367	A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. 2014 , 74, 665-74	414
1366	Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. 2014 , 1102, 287-324	61
1365	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. 2014 , 28, 993-1000	81
1364	Immune modulation in cancer with antibodies. 2014 , 65, 185-202	366
1363	Checkpoint blocking antibodies in cancer immunotherapy. 2014 , 588, 368-76	184
1362	The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. 2014 , 7, 1-17	72
1361	Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. 2014 , 21, 262-71	62
1360	MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. 2014 , 75, 348-53	133
1359	Immunotherapy for prostate cancer: recent developments and future challenges. 2014 , 33, 641-55	49
1358	Generation of a monoclonal antibody recognizing mouse PD-1. 2014 , 33, 361-4	1
1357	Glioma Cell Biology. 2014 ,	2
1356	Recent developments in the medical and surgical treatment of melanoma. 2014 , 64, 171-85	46
1355	Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. 2014 , 92, 195-203	79
1354	Current management of advanced melanoma: a transformed landscape. 2014 , 84, 612-7	11

1353	Current perspectives on immunotherapy. 2014 , 41 Suppl 5, S14-29	23
1352	Mechanism of action of immunotherapy. 2014 , 41 Suppl 5, S3-13	89
1351	Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?. 2014 , 25, 656-64	71
1350	PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. 2014 , 25, 2433-2442	98
1349	The path to reactivation of antitumor immunity and checkpoint immunotherapy. 2014 , 2, 926-36	22
1348	Vaccine therapies for patients with glioblastoma. 2014 , 119, 531-46	24
1347	Tracking cellular and immune therapies in cancer. 2014 , 124, 257-96	24
1346	LSECTin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. 2014 , 74, 3418-28	180
1345	Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. 2014 , 53, 1-9	38
1344	No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. 2014 , 8, 1140-58	39
1343	Attenuation of IFN- γ -induced B7-H1 expression by 15-deoxy-delta(12,14)-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway. 2014 , 112, 82-9	16
1342	B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. 2014 , 116, 1163-8	50
1341	PD-1 regulates extrathymic regulatory T-cell differentiation. 2014 , 44, 2603-16	68
1340	Programmed cell death ligand 1 expression in osteosarcoma. 2014 , 2, 690-698	135
1339	The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. 2014 , 193, 3835-41	127
1338	Synergistic effects of IL-4 and TNF α on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. 2014 , 12, 151	35
1337	Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. 2014 , 74, 5458-68	704
1336	Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. 2014 , 211, 1905-18	151

1335	TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells. 2014 , 193, 2218-29	51
1334	PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. 2014 , 63, 395-406	111
1333	B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation. 2014 , 63, 859-67	11
1332	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. 2014 , 146, 15-24	375
1331	PD-L1 expression in triple-negative breast cancer. 2014 , 2, 361-70	698
1330	Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. 2014 , 2, 3	371
1329	Biology of breast cancer during pregnancy using genomic profiling. 2014 , 21, 545-54	48
1328	PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. 2014 , 2, 320-31	109
1327	Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival. 2014 , 70, 954-6	17
1326	Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. 2014 , 10, 927-61	24
1325	Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. 2014 , 20, 5064-74	1661
1324	Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. 2014 , 31, 960	16
1323	The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression. 2014 , 35, 2923-9	26
1322	Immunocompetent murine models for the study of glioblastoma immunotherapy. 2014 , 12, 107	131
1321	Immunologic and clinical effects of targeting PD-1 in lung cancer. 2014 , 96, 214-23	62
1320	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. 2014 , 32, 1020-30	1684
1319	Tumor-Induced Immune Suppression. 2014 ,	1
1318	In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. 2014 , 2, 846-56	402

1317	Self-reactive T cells: suppressing the suppressors. 2014 , 63, 313-9	7
1316	Immunotherapy in the treatment of non-small cell lung cancer. 2014 , 85, 101-9	95
1315	PD-1/PD-Ls pathways between CD4(+) T cells and pleural mesothelial cells in human tuberculous pleurisy. 2014 , 94, 131-9	9
1314	Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?. 2014 , 41, 126-32	40
1313	The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. 2014 , 50, 627-32	161
1312	Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. 2014 , 40, 121-7	113
1311	The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. 2014 , 10, 19-30	33
1310	Updates on immunotherapy in non-small cell lung cancer. 2014 , 14, 411-8	2
1309	Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. 2014 , 89, 504-19	63
1308	Toll-like receptors in lymphoid malignancies: double-edged sword. 2014 , 89, 262-83	17
1307	Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes. 2014 , 10, 2827-34	14
1306	B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients. 2014 , 8, 1195-1201	44
1305	Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10. 2014 , 9, 85	27
1304	PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. 2014 , 21, 231-7	104
1303	Potential of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. 2014 , 1, 14004	28
1302	Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon- γ treatment. 2014 , 105, 1236-44	22
1301	Immunologic Approaches to Lung Cancer Therapy. 2014 , 454-463	
1300	Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer. 2014 , 31, 1191-8	36

1299	Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. 2015 , 23, 541-9	138
1298	Nanomedicines Targeting the Tumor Microenvironment. 2015 , 21, 314-21	53
1297	Combination immunotherapy with CTLA-4 and PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. 2015 , 3, 21	122
1296	[Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now?]. 2015 , 46, 473-80	
1295	Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. 2015 , 94, e515	79
1294	Associations among pretreatment tumor necrosis and the expression of HIF-1 α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof. 2015 , 51, 1004-1010	47
1293	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. 2015 , 106, 945-50	61
1292	Mathematical analysis and classification of tumor immune dynamics in T cell transfer treatment. 2015 , 6, 54-70	3
1291	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. 2015 , 5, 13110	246
1290	Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. 2015 , 5, 15659	93
1289	Principles of Targeted Immunotherapy. 2015 , 27-38	
1288	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. 2015 , 126, 2193-201	312
1287	A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. 2015 , 7, 450-63	28
1286	A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. 2015 , 9, 35-43	4
1285	PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. 2015 , 10, 189	56
1284	The role of combined radiation and immunotherapy in breast cancer treatment. 2015 , 4, 347-354	2
1283	Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. 2015 , 13, 319	21
1282	Targeting the immune system: a new horizon of cancer therapies. 2015 , 2, 10-12	1

1281	Update on checkpoint blockade therapy for lymphoma. 2015 , 3, 33	10
1280	Inhibitory receptors as targets for cancer immunotherapy. 2015 , 45, 1892-905	84
1279	Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. 2015 , 38, 119-25	56
1278	Genomic alterations underlying immune privilege in malignant lymphomas. 2015 , 22, 343-54	15
1277	Pembrolizumab in the management of metastatic melanoma. 2015 , 2, 315-325	4
1276	Immunotherapy for Advanced Lung Cancer. 2015 , 21, 383-91	6
1275	Natural Killer Cells Differentiate Human Adipose-Derived Stem Cells and Modulate Their Adipogenic Potential. 2015 , 136, 503-510	4
1274	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. 2015 , 27, 384-91	15
1273	Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT. 2015 , 40, e528-9	55
1272	Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. 2015 , 54, 11760-4	175
1271	Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma. 2015 , 38, 285-91	27
1270	Immunotherapies for bladder cancer: a new hope. 2015 , 25, 586-96	13
1269	Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. 2015 , e291-7	4
1268	Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. 2015 , 6, 41228-36	140
1267	Prognostic and predictive value of PDL1 expression in breast cancer. 2015 , 6, 5449-64	313
1266	Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. 2015 , 6, 8261-70	44
1265	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. 2015 , 125, 3384-91	815
1264	Targeting PD-1/PD-L1 in lung cancer: current perspectives. 2015 , 6, 55-70	9

1263	Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer. 2015 , 5,	
1262	Immunosuppressive Microenvironment in Head and Neck Cancer. 2015 ,	1
1261	Cancer immunotherapy: harnessing the immune system to battle cancer. 2015 , 125, 3335-7	597
1260	Biomarkers of Response to Immune Modulatory Therapies in Cancer. 2015 , 06,	
1259	New developments in the management of advanced melanoma - role of pembrolizumab. 2015 , 8, 2535-43	13
1258	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. 2015 , 7, 2397-414	51
1257	Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment. 2015 , 2, 4-15	
1256	Zielgerichtete Therapien gegen PD-1 bei malignen Erkrankungen des Lymphsystems: Biologischer Hintergrund, klinische Herausforderungen und Chancen. 2015 , 2, 8-14	
1255	Regulatory Roles of Non-Coding RNAs in Colorectal Cancer. 2015 , 16, 19886-919	50
1254	Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?. 2015 , 6, 258	9
1253	Editorial: "Cancer Immunotherapy: Lights and Shadows". 2015 , 6, 350	1
1252	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. 2015 , 6, 505	71
1251	Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. 2015 , 5, 153	98
1250	Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. 2015 , 8, 929-37	21
1249	Association between B7-H1 expression and bladder cancer: a meta-analysis. 2015 , 14, 1277-86	2
1248	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. 2015 , 7, 5889-901	15
1247	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. 2015 , 6, 7-17	48
1246	Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF- κ B. 2015 , 10, e0123410	145

1245	High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. 2015 , 10, e0142656	138
1244	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. 2015 , 10, e0130142	339
1243	B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells. 2015 , 10, e0135528	48
1242	PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. 2015 , 10, e0136476	43
1241	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. 2015 , 8, 2949-57	6
1240	Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. 2015 , 9, 901-9	116
1239	Monoclonal Antibodies for the Treatment of Cancer. 2015 , 683-694.e3	
1238	Principles of Cancer Immunobiology and Immunotherapy of Solid Tumors. 2015 ,	3
1237	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. 2015 , 6, 13506-19	87
1236	Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. 2015 , 7, 2449-58	26
1235	Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. 2015 , 10, 426-30	125
1234	Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. 2015 , 26, 1813-1823	162
1233	Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors. 2015 , 13, 161	19
1232	Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. 2015 , 14, 487-98	165
1231	Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer. 2015 , 62, 316-24	18
1230	Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. 2015 , 4, e237	82
1229	Programmed death-1 checkpoint blockade in acute myeloid leukemia. 2015 , 15, 1191-203	50
1228	A gender factor in shaping T-cell immunity to melanoma. 2015 , 5, 8	11

1227	PD-1/PD-L1 inhibitors. 2015 , 23, 32-8	358
1226	The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. 2015 , 26, 1980-1987	78
1225	EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF- κ B. 2015 , 463, 95-101	104
1224	Costimulation in Lymphomas and Cancers. 2015 , 185-254	4
1223	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. 2015 , 94, 1545-52	56
1222	New strategies to develop new medications for lung cancer and metastasis. 2015 , 34, 265-75	10
1221	Biomarkers for personalized medicine in GI cancers. 2015 , 45, 14-27	9
1220	Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. 2015 , 42, 201-15, viii	13
1219	Immunostimulators and Immunomodulators in Cancer Treatment. 2015 , 411-431	
1218	Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay. 2015 , 17, 976-87	8
1217	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. 2015 , 75, 2928-36	150
1216	Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. 2015 , 21, 712-20	180
1215	PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. 2015 , 3, 620-30	53
1214	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. 2015 , 3, 1158-64	205
1213	Programmed death-1 controls T cell survival by regulating oxidative metabolism. 2015 , 194, 5789-800	76
1212	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. 2015 , 26, 1488-93	179
1211	Beyond adjuvants: immunomodulation strategies to enhance T cell immunity. 2015 , 33 Suppl 2, B21-8	19
1210	Kidney Cancer. 2015 ,	1

1209	Cancer and the Immune System: Basic Concepts and Targets for Intervention. 2015 , 42, 523-38	168
1208	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. 2015 , 3, 855-63	53
1207	Immunotherapeutic advancements for glioblastoma. 2015 , 5, 12	30
1206	DNA vaccines, electroporation and their applications in cancer treatment. 2015 , 11, 1889-900	45
1205	Developments in T Cell Based Cancer Immunotherapies. 2015 ,	
1204	Therapeutic Antibodies in Cancer Therapy. 2015 , 95-120	0
1203	Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337). 2015 , 21, 5445-52	25
1202	IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. 2015 , 15, 771-83	160
1201	Erfolge und Grenzen zielgerichteter Krebstherapien beim Melanom. 2015 , 3, 65-72	
1200	Current status of checkpoint inhibitors in lymphoma. 2015 , 4, 167-174	
1199	Current and Emerging Perspectives on Immunotherapy for Melanoma. 2015 , 42 Suppl 3, S3-S11	17
1198	T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. 2015 , 8, 93	101
1197	Therapeutic options in advanced squamous cell lung carcinoma. 2015 , 4, 75-86	
1196	Alteration of CD4 T cell subsets in metastatic lymph nodes of human gastric cancer. 2015 , 34, 639-47	9
1195	[Rationale, visions and limits of Immuno-oncology: Checkpoint inhibition as a new pillar of tumor therapy]. 2015 , 38 Suppl 3, 2-5	1
1194	[What opportunities does Immuno-oncology indicate for overarching long-term survival?]. 2015 , 38 Suppl 3, 6-11	1
1193	Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. 2015 , 27, 443-52	216
1192	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. 2015 , 3, 326-32	232

1191	Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. 2015 , 51, 221-8	218
1190	Immunotherapy for head and neck squamous cell carcinoma. 2015 , 51, 299-304	16
1189	CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. 2015 , 4, 661-72	80
1188	Immune-mediated antitumor effect by type 2 diabetes drug, metformin. 2015 , 112, 1809-14	331
1187	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. 2015 , 33, 23-35	246
1186	Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. 2015 , 29, 1441-4	147
1185	Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. 2015 , 3, 236-44	95
1184	Immune Checkpoint Blockade in Cancer Therapy. 2015 , 33, 1974-82	1690
1183	Immune checkpoint modulation: rational design of combination strategies. 2015 , 150, 23-32	62
1182	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. 2015 , 7, 12-21	20
1181	Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. 2015 , 15, 69-83	10
1180	Building immunity to cancer with radiation therapy. 2015 , 368, 198-208	57
1179	[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway]. 2015 , 71, 44-56	6
1178	Can oncology recapitulate paleontology? Lessons from species extinctions. 2015 , 12, 273-85	24
1177	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. 2015 , 14, 847-56	1248
1176	Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. 2015 , 34, 129-44	9
1175	PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. 2015 , 13, 5	55
1174	Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. 2015 , 34, 5411-7	39

1173	Nivolumab in NSCLC: latest evidence and clinical potential. 2015 , 7, 85-96	164
1172	Evaluation of Immune Restoration Potential of PD-1 Blockers. 2015 , 36, 567-72	1
1171	Nivolumab in melanoma: latest evidence and clinical potential. 2015 , 7, 97-106	108
1170	Nivolumab and Olaparib. 2015 , 50, 356-66	2
1169	Evolving Concepts: Immunity in Oncology from Targets to Treatments. 2015 , 2015, 847383	20
1168	Nivolumab: targeting PD-1 to bolster antitumor immunity. 2015 , 11, 1307-26	123
1167	B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor. 2015 , 9, 1833-1838	28
1166	Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers. 2015 , 134, 208-14	15
1165	Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. 2015 , 128, 263-307	85
1164	Combination cancer immunotherapy and new immunomodulatory targets. 2015 , 14, 561-84	806
1163	Immune Checkpoint Inhibition in Renal Cell Carcinoma. 2015 , 259-279	
1162	Inflammation and Lung Cancer: Molecular Pathology. 2015 , 69-93	
1161	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2R β Immunodeficient Mice. 2015 , 75, 3466-78	98
1160	Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. 2015 , 21, 3969-76	172
1159	PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. 2015 , 3, 946-55	57
1158	Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?. 2015 , 16, 59	13
1157	PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. 2015 , 32, 212	67
1156	Inflammation and Lung Cancer. 2015 ,	0

1155	Challenges and future perspectives of T cell immunotherapy in cancer. 2015 , 166, 117-33	37
1154	Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. 2015 , 6, 127	39
1153	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. 2015 , 21, 4607-18	214
1152	Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia. 2015 , 134, 255-62	31
1151	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. 2015 , 709-738.e8	
1150	Nivolumab in renal cell carcinoma. 2015 , 15, 1049-60	4
1149	OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. 2015 , 5, 34	161
1148	Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. 2015 , 7, 641-52	38
1147	Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. 2015 , 6, 46	60
1146	Best practice in the treatment of advanced squamous cell lung cancer. 2015 , 9, 224-35	14
1145	Tumor infiltrating lymphocytes in ovarian cancer. 2015 , 16, 807-20	173
1144	Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. 2015 , 85, 703.e1-6	88
1143	Anti-PD-1-targeted therapies focusing on lymphatic malignancies: biological rationale, clinical challenges and opportunities. 2015 , 133, 129-35	8
1142	Immuno-regulatory antibodies for the treatment of cancer. 2015 , 15, 787-801	36
1141	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. 2015 , 46, 357-65	185
1140	Programmed cell death-1 inhibition in lymphoma. 2015 , 16, e234-45	40
1139	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. 2015 , 33, 2013-20	337
1138	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. 2015 , 21, 3140-8	97

1137	The future of immune checkpoint therapy. 2015 , 348, 56-61	2733
1136	Pembrolizumab for the treatment of non-small-cell lung cancer. 2015 , 372, 2018-28	3943
1135	Immunotherapy in prostate cancer. 2015 , 16, 34	6
1134	Immunotherapy for lung cancer: for whom the bell tolls?. 2015 , 36, 1411-22	14
1133	Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. 2015 , 13, 14	38
1132	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. 2015 , 88, 254-9	55
1131	Microencapsulation of tumor lysates and live cell engineering with MIP-3 α s an effective vaccine. 2015 , 53, 554-65	7
1130	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. 2015 , 3, 399-411	289
1129	Clinically feasible approaches to potentiating cancer cell-based immunotherapies. 2015 , 11, 851-69	51
1128	Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma. 2015 , 24, 897-912	10
1127	Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. 2015 , 42, 363-77	83
1126	An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. 2015 , 4, e976052	64
1125	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. 2015 , 7, 279ra41	369
1124	On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. 2015 , 7, 280sr1	113
1123	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. 2015 , 21, 3052-60	152
1122	Inflammation and Immunity in Cancer. 2015 ,	1
1121	Metastasectomy for stage IV melanoma. 2015 , 24, 279-98	18
1120	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. 2015 , 16, 375-84	1881

1119	Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. 2015 , 21, 976-84	155
1118	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. 2015 , 67, 4-17	152
1117	Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. 2015 , 88, 154-9	113
1116	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. 2015 , 33, 2004-12	859
1115	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. 2015 , 23, 1380-1390	67
1114	Safety of pembrolizumab for the treatment of melanoma. 2015 , 14, 957-64	22
1113	B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity. 2015 , 3, 184-95	28
1112	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. 2015 , 38, 1-11	270
1111	Clinicoradiological spectrum of reversible splenic lesion syndrome (RESLES) in adults: a retrospective study of a rare entity. 2015 , 94, e512	39
1110	Immune checkpoint inhibition in lymphoid disease. 2015 , 170, 291-304	18
1109	A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. 2015 , 68, 267-79	144
1108	CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. 2015 , 194, 3475-86	329
1107	Clinical deployment of antibodies for treatment of melanoma. 2015 , 67, 18-27	10
1106	Anti-PD-1 therapy in melanoma. 2015 , 42, 466-73	34
1105	CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. 2015 , 64, 677-88	59
1104	Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. 2015 , 42, 495-505	36
1103	Immune checkpoint blockade: a common denominator approach to cancer therapy. 2015 , 27, 450-61	2410
1102	Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. 2015 , 161, 205-14	1388

1101	A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. 2015 , 13, 265-72	146
1100	Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice. 2015 , 3, 631-40	46
1099	Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells. 2015 , 64, 1287-93	14
1098	Immunotherapeutic options on the horizon in breast cancer treatment. 2015 , 156, 90-101	15
1097	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. 2015 , 28, 1535-44	58
1096	PD-1 and PD-L1 blockade in gastrointestinal malignancies. 2015 , 41, 893-903	44
1095	Immunosuppression associated with chronic inflammation in the tumor microenvironment. 2015 , 36, 1085-93	192
1094	Predictive biomarkers in precision medicine and drug development against lung cancer. 2015 , 34, 295-309	29
1093	PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. 2015 , 3, 110-5	43
1092	Immune checkpoints and immunotherapy for colorectal cancer. 2015 , 3, 289-97	61
1091	Immunosuppressive mechanisms in glioblastoma. 2015 , 17 Suppl 7, vii9-vii14	195
1090	Several immune escape patterns in non-Hodgkin's lymphomas. 2015 , 4, e1026530	62
1089	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. 2015 , 21, 5427-33	196
1088	Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. 2015 , 64, 1553-63	19
1087	Emerging therapeutic approaches in renal cell carcinoma. 2015 , 15, 1305-14	12
1086	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. 2015 , 41, 914-24	33
1085	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. 2015 , 32, 821-34	10
1084	Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. 2015 , 26, 2062-9	109

1083	MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. 2015 , 36, 9049-57	34
1082	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. 2015 , 3, 1375-85	246
1081	Lung cancer: Biology and treatment options. 2015 , 1856, 189-210	322
1080	Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. 2015 , 18, 325-32	117
1079	Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. 2015 , 4, e1016700	156
1078	Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. 2015 , 56, 414-25	90
1077	The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. 2015 , 4, e1016709	56
1076	Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. 2015 , 11, 1201-8	10
1075	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. 2015 , 162, 1229-41	1457
1074	Role of the Tumor Microenvironment in Breast Cancer. 2015 , 82, 142-52	185
1073	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. 2015 , 162, 1242-56	365
1072	An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. 2015 , 22, 454-62	48
1071	FcBs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. 2015 , 28, 285-95	179
1070	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. 2015 , 2, 41-50	6
1069	Antibody-based immunotherapy of solid cancers: progress and possibilities. 2015 , 7, 923-39	17
1068	B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway. 2015 , 195, 3584-95	9
1067	Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. 2015 , 34, 141	115
1066	PDL-1/PDL-2 blockade in mice dendritic cells by RNAi techniques to induce antitumor immunity. 2015 , 7, 1145-58	8

1065	Kidney cancer and 2014: is innovation really over?. 2015 , 11, 1437-49	1
1064	Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer. 2015 , 16, 385-90	94
1063	Turning Radiotherapy into an Effective Systemic Anti-cancer Treatment in Combination with Immunotherapy. 2015 , 27, 696-9	10
1062	Programmed cell death-1 is expressed in large retinal ganglion cells and is upregulated after optic nerve crush. 2015 , 140, 1-9	9
1061	Active Immunotherapy of Cancer. 2015 , 44, 817-36	32
1060	Overview of current immunotherapeutic strategies for glioma. 2015 , 7, 1073-104	32
1059	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. 2015 , 9, 1936-65	55
1058	Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. 2015 , 42 Suppl 3, S12-9	22
1057	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. 2015 , 9, 2054-62	60
1056	The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. 2015 , 19, 201-11	66
1055	The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. 2015 , 62, 190-197	23
1054	Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets. 2015 , 147, 63-79	23
1053	Vaccine therapies in malignant glioma. 2015 , 15, 508	16
1052	Renal Cell Carcinoma. 2015 ,	
1051	Targeting the bone marrow microenvironment in multiple myeloma. 2015 , 263, 160-72	223
1050	Clinical blockade of PD1 and LAG3--potential mechanisms of action. 2015 , 15, 45-56	398
1049	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. 2015 , 33, 1430-7	735
1048	Immunotherapy for malignant gliomas. 2015 , 163, 143-58	9

1047	B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. 2015 , 194, 560-74	45
1046	Combination of radiotherapy and immune checkpoint inhibitors. 2015 , 25, 28-33	107
1045	The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. 2015 , 148, 132-53	43
1044	Current Understanding and Treatment of Gliomas. 2015 ,	5
1043	Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. 2015 , 50, 65-75	73
1042	The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. 2015 , 5, 43-51	890
1041	Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. 2015 , 20, 273-81	89
1040	Immunotherapy in Colorectal Cancer. 2016 ,	
1039	Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. 2016 , 7, 81341-81356	46
1038	Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. 2016 , 7, 33498-511	70
1037	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. 2016 , 7, 56233-56240	43
1036	Regulatory T Cells in Tumor Immunity. 2016 , 451-459	2
1035	Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis. 2016 , 9, 2649-54	25
1034	Immune Checkpoint Blockade Therapy: Merits and Demerits. 2016 , 7,	
1033	Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. 2016 , 7, 32113-28	81
1032	PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression. 2016 , 5, S1396-S1399	5
1031	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. 2016 , 9, 5855-5866	8
1030	Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?. 2016 , 10, 293	38

1029	Effects of lung cancer cell-associated B7-H1 on T-cell proliferation in vitro and in vivo. 2016 , 49,	0
1028	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. 2016 , 17, 771-6	12
1027	High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. 2016 , 7, 33035-45	35
1026	Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy. 2016 , 16, 134-9	5
1025	Association of the programmed cell death-1 PD1.5 C>T polymorphism with cervical cancer risk in a Chinese population. 2016 , 15,	10
1024	Antitumor Effect of Zhihuang Fuzheng Soft Capsules on Tumor-Bearing Mice. 2016 , 2016, 7503726	
1023	Immunotherapy for Glioblastoma. 2016 , 7,	
1022	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. 2016 , 1,	52
1021	The head and neck cancer immune landscape and its immunotherapeutic implications. 2016 , 1, e89829	356
1020	Immunotherapy in urothelial carcinoma: fade or future standard?. 2016 , 5, 662-667	2
1019	Immune checkpoint therapy for pancreatic cancer. 2016 , 22, 9457-9476	60
1018	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. 2016 , 7, 76565-76576	74
1017	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. 2016 , 2016, 9850690	15
1016	Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. 2016 , 2016, 3850839	25
1015	Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. 2016 , 2016, 9839685	15
1014	Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. 2016 , 2016, 8941260	110
1013	Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. 2016 , 2016, 4757405	29
1012	PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. 2016 , 7, 784-93	100

1011	Development of Novel Immunotherapies for Multiple Myeloma. 2016 , 17,	18
1010	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. 2016 , 6, 1629-40	138
1009	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. 2016 , 4, 27	83
1008	T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. 2016 , 7, 353	45
1007	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. 2016 , 7, 550	282
1006	Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. 2016 , 7, 610	87
1005	Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma. 2016 , 17, 506	72
1004	PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays. 2016 , 17,	16
1003	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. 2016 , 17,	93
1002	Mechanisms of Immune Escape in Cancer. 2016 , 75, 152-155	
1001	PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. 2016 , 11, e0160485	25
1000	Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis. 2016 , 11, e0152326	3
999	Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. 2016 , 11, e0161779	125
998	PD-L1 expression in human cancers and its association with clinical outcomes. 2016 , 9, 5023-39	370
997	Immune Evasion Strategies of Glioblastoma. 2016 , 3, 11	152
996	Radiation-induced immune responses: mechanisms and therapeutic perspectives. 2016 , 51, 157-163	31
995	Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. 2016 , 9, 5101-16	26
994	PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. 2016 , 9, 489-502	40

993	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. 2016 , 2, 15-25	21
992	Immune checkpoint blockade therapy for bladder cancer treatment. 2016 , 57 Suppl 1, S98-S105	14
991	War-winning weapons. 2016 , 17, S18-S18	
990	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. 2016 , 7, 73068-73079	60
989	Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma. 2016 , 22, 17-22	13
988	Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. 2016 , 22, 130-7	29
987	Immune Checkpoint Therapy in Melanoma. 2016 , 22, 73-80	9
986	Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. 2016 , 39, 171-80	65
985	Pembrolizumab (Keytruda). 2016 , 12, 2777-2789	127
984	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. 2016 , 8, 821-37	96
983	Myeloid-derived suppressor cells as effectors of immune suppression in cancer. 2016 , 139, 1915-26	67
982	Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. 2016 , 40, 443-53	35
981	Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors. 2016 , 40, 1133-42	62
980	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. 2016 , 34, 596-603	35
979	BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis. 2016 , 5, e1185582	33
978	Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. 2016 , 16, 310	70
977	The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. 2016 , 101, 794-802	62
976	Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. 2016 , 114, 36-43	63

975	A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer. 2016 , 36, 313-320	3
974	Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells. 2016 , 380, 424-433	51
973	Control of Immune Response to Allogeneic Embryonic Stem Cells by CD3 Antibody-Mediated Operational Tolerance Induction. 2016 , 16, 454-67	6
972	Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. 2016 , 172, 685-98	38
971	Immunotherapy for breast cancer: past, present, and future. 2016 , 35, 525-546	27
970	Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul. 2016 , 4, 1001-1006	18
969	Mesenchymal stromal cells for the treatment of autoimmune diseases. 2016 , 794-813	
968	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. 2016 , 1,	74
967	5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. 2016 , 4, 65	66
966	The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. 2016 , 6, 19740	108
965	B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu. 2016 , 36, 231-8	12
964	Model-based genotype-phenotype mapping used to investigate gene signatures of immune sensitivity and resistance in melanoma micrometastasis. 2016 , 6, 24967	14
963	Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. 2016 , 4, 61	63
962	A New VISTA on combination therapy for negative checkpoint regulator blockade. 2016 , 4, 86	27
961	Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. 2016 , 1, e000083	45
960	Immune checkpoint inhibitors for hepatocellular carcinoma. 2016 , 3, 201-211	4
959	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. 2016 , 1, 16025	25
958	PD-L1 is upregulated by EBV-driven LMP1 through NF- κ B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. 2016 , 9, 109	150

957	Renal effects of immune checkpoint inhibitors. 2017 , 32, 936-942	48
956	Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. 2016 , 1,	58
955	Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma. 2016 , 107, 1736-1744	41
954	B lymphocytes and cancer: a love-hate relationship. 2016 , 2, 747-757	187
953	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. 2016 , 14, 173	77
952	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. 2016 , 6, 25952	29
951	Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. 2016 , 107, 1563-1571	106
950	Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer. 2016 , 24, 392-7	197
949	Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma. 2016 , 1, 75-81	7
948	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF α Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. 2016 , 39, 343-354	17
947	Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. 2016 , 95, e5541	80
946	Programmed death-ligand 1 expression in rectal cancer. 2016 , 48, 352-356	13
945	Immune-related endocrine disorders in novel Immune checkpoint inhibition therapy. 2016 , 3, 252-256	15
944	PDX ou xBogreffe d'ivB de la tumeur du patient, la renaissance d'un modle oubliB son implication dans la recherche et la clinique de demain. 2016 , 4, 237-245	0
943	ImmunothBapie : les checkpoints. 2016 , 8, 387-398	
942	The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. 2016 , 5, e1247135	122
941	Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses. 2016 , 118, 267-71	23
940	Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma. 2016 , 101, 1361-9	47

939	GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. 2016 , 24, 1135-1149	190
938	Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. 2016 ,	2
937	Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. 2016 , 34, 347-54	43
936	High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. 2016 , 59, 152-159	137
935	Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma. 2016 , 4, 463-71	59
934	Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. 2016 , 48, 428-439	26
933	Therapeutic Antibodies in Cancer Therapy. 2016 , 917, 95-120	26
932	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. 2016 , 76, 925-45	100
931	Malignant melanoma-The cradle of anti-neoplastic immunotherapy. 2016 , 106, 25-54	22
930	PD-L1 Expression in Lung Cancer. 2016 , 11, 964-75	201
929	Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. 2016 , 44, 955-72	315
928	Targeting PD-L1 for non-small-cell lung cancer. 2016 , 8, 747-58	10
927	Farrerol inhibited angiogenesis through Akt/mTOR, Erk and Jak2/Stat3 signal pathway. 2016 , 23, 686-93	21
926	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. 2016 , 8, 733-46	19
925	Phase I study to evaluate toxicity and feasibility of intratumoral injection of E9gal glycolipids in patients with advanced melanoma. 2016 , 65, 897-907	8
924	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). 2016 , 27, 1492-504	280
923	Handbook of HER2-Targeted Agents in Breast Cancer. 2016 ,	
922	Les anticorps monoclonaux dirigés contre les checkpoints immunologiques : de nouvelles approches d'immunothérapie en onco-hématologie. 2016 , 4, 5-12	2

921	PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. 2016 , 22, 1173-1184	121
920	Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. 2016 , 35, 699-708	48
919	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. 2016 , 57, 1269-80	4
918	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. 2016 , 27, 1482-92	335
917	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. 2016 , 16, 275-87	1444
916	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. 2016 , 16, 989-1004	9
915	The role of neoantigens in response to immune checkpoint blockade. 2016 , 28, 411-9	88
914	TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. 2016 , 76, 2087-93	55
913	The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review. 2016 , 142, 184-189	14
912	Emerging Opportunities and Challenges in Cancer Immunotherapy. 2016 , 22, 1845-55	172
911	Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. 2016 , 60, 12-25	240
910	Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?. 2016 , 34, 215-20	11
909	Immune checkpoint inhibition in ovarian cancer. 2016 , 28, 339-48	96
908	Expression of PD-L1 in mastocytosis. 2016 , 74, 1010-2	4
907	Expression of T-bet and GATA-3 in early mycosis fungoides and spongiotic dermatitis. 2016 , 74, 1012-4	5
906	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. 2016 , 12, 2219-31	33
905	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. 2016 , 8, 583-600	52
904	Recent developments in the use of immunotherapy in non-small cell lung cancer. 2016 , 10, 781-98	23

903	Emerging therapeutics in refractory renal cell carcinoma. 2016 , 17, 1225-32	12
902	Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma. 2016 , 22, 4727-34	55
901	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. 2016 , 33, 59	20
900	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. 2016 , 5, e1131379	73
899	PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. 2016 , 128, 1374-81	92
898	Perspectives for immunotherapy in endocrine cancer. 2016 , 23, R469-84	10
897	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. 2016 , 17, 1374-1385	818
896	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. 2016 , 3, 195-202	10
895	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. 2016 , 3, 268-277	3
894	Immunotherapy for malignant mesothelioma: reality check. 2016 , 16, 1167-1176	9
893	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. 2016 , 76, 6964-6974	200
892	Programmed Death 1 Expression on CD4 T Cells Predicts Mortality after Allogeneic Stem Cell Transplantation. 2016 , 22, 2172-2179	18
891	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. 2016 , 5, e1235107	77
890	TGF β -Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. 2016 , 6, 1366-1381	131
889	Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models. 2016 , 65, 1511-1522	13
888	Targeting the Bone Marrow Microenvironment. 2016 , 169, 63-102	9
887	Coming-of-Age of Antibodies in Cancer Therapeutics. 2016 , 37, 1009-1028	69
886	Rescuing defective tumor-infiltrating T-cell proliferation in glioblastoma patients. 2016 , 12, 2924-2929	28

885	Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion. 2016 , 12, 2161-2168	8
884	Prolonged PD1 Expression on Neonatal V β Lymphocytes Dampens Proinflammatory Responses: Role of Epigenetic Regulation. 2016 , 197, 1884-92	14
883	Metastatic melanoma and immunotherapy. 2016 , 172, 105-110	31
882	PD-1/PD-L1, Only a Piece of the Puzzle. 2016 , 140, 1187-1188	7
881	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. 2016 , 61, 152-8	40
880	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. 2016 , 34, 677-684	22
879	Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. 2016 , 23, 3786-3791	1
878	PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. 2016 , 27, 2103-10	94
877	Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. 2016 , 5, 1481-91	58
876	Malignant melanoma showing a rapid response to nivolumab. 2016 , 57, 61-3	3
875	The immune system and cancer evasion strategies: therapeutic concepts. 2016 , 279, 541-62	146
874	Lymphocyte-activation gene-3, an important immune checkpoint in cancer. 2016 , 107, 1193-7	115
873	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. 2016 ,	1
872	Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry. 2016 , 65, 1317-1323	13
871	Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?. 2016 , 89, 20160472	28
870	Clinical significance of T cell metabolic reprogramming in cancer. 2016 , 5, 29	51
869	Cancer Immunotherapy by Checkpoint Blockade. 2016 , 561-580	
868	PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?. 2016 , 27, 1658-9	3

867	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. 2016 , 27, 1953-8	195
866	Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. 2016 , 120, 185-94	72
865	Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. 2016 , 5, 1810-20	38
864	Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse. 2016 , 7, 10823	36
863	Bioanalytical qualification of clinical biomarker assays in plasma using a novel multi-analyte Simple Plex platform. 2016 , 8, 2415-2428	9
862	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. 2016 , 7, 12632	408
861	B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8 T cells. 2016 , 6, 36722	26
860	Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells. 2016 , 65, 1477-1489	29
859	Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence. 2016 , 96, 1156-1164	7
858	PD-L1 expression is associated with advanced non-small cell lung cancer. 2016 , 12, 921-927	17
857	Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. 2016 , 12, 1089-96	15
856	Advances in immunotherapy for melanoma management. 2016 , 12, 2501-2511	13
855	Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment. 2016 , 166, 288-298	397
854	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. 2016 , 8, 775-84	19
853	Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. 2016 , 99, 117-9	70
852	Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. 2016 , 4, 779-88	66
851	Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome. 2016 , 23, 508-515	36
850	Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. 2016 , 5, e1202390	25

849	Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. 2016 , 30, 397-405	31
848	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. 2016 , 64, 2038-2046	242
847	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. 2016 , 16, 1209-23	14
846	WITHDRAWN: Prognostic Significance of Programmed Cell Death-Ligand 1 Expression in Patients With Resected Lung Adenocarcinoma. 2016 ,	3
845	Deubiquitination and Stabilization of PD-L1 by CSN5. 2016 , 30, 925-939	332
844	Magneto-nanosensor platform for probing low-affinity protein-protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction. 2016 , 7, 12220	23
843	BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. 2016 , 8, 1351-1353	6
842	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. 2016 , 8, 328rv4	1281
841	Nivolumab in melanoma. 2016 , 16, 1247-1261	16
840	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. 2016 , 7, 866-877	26
839	Immune checkpoint inhibitors for cancer treatment. 2016 , 39, 1577-1587	29
838	The Development of Systemic Therapies for Esophageal and Gastric Cancers. 2016 , 153-170	
837	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. 2016 , 375, 1767-1778	661
836	Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue. 2016 , 140, 1259-1266	52
835	Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy. 2016 , 39, 306-15	7
834	Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma. 2016 , 26, 429-41	32
833	Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management. 2016 , 26, 548-55	7
832	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. 2016 , 22, 257-66	27

831	Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators. 2016 , 11, 450-66	76
830	Checkpoint inhibition in meningiomas. 2016 , 8, 721-31	18
829	Mathematical model of tumor-immune surveillance. 2016 , 404, 312-330	38
828	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). 2016 , 33, 80	27
827	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. 2016 , 44, 1255-69	554
826	NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. 2016 , 197, 953-61	62
825	Combinatorial approach to cancer immunotherapy: strength in numbers. 2016 , 100, 275-90	65
824	Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N. 2016 , 11, 44	50
823	The PD-1:PD-L1 immune inhibitory checkpoint in <i>Helicobacter pylori</i> infection and gastric cancer: a comprehensive review and future perspectives. 2016 , 1, 4-11	8
822	Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. 2016 , 21, 946-952	33
821	Immunotherapy for Head and Neck Squamous Cell Carcinoma. 2016 , 3, 74-81	6
820	Dendritic cell vaccines: A review of recent developments and their potential pediatric application. 2016 , 12, 2232-9	23
819	Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. 2016 , 18, 50	42
818	Mismatch in epitope specificities between IFN γ -inflamed and uninfamed conditions leads to escape from T lymphocyte killing in melanoma. 2016 , 4, 10	17
817	Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing Irradiation. 2016 , 76, 4673-83	49
816	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. 2016 , 2, 1217-22	165
815	Biomarkers for Wilms Tumor: A Systematic Review. 2016 , 196, 1530-1535	44
814	Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. 2016 , 56, 157-69	75

813	PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women: A Hospital-Based Observational Study. 2016 , 95, e3760	31
812	Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. 2016 , 5, e1062967	37
811	Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. 2016 , 37, 4251-61	62
810	CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. 2016 , 4, 259-68	54
809	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. 2016 , 16, 389-96	29
808	New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy. 2016 , 14, 61-65	
807	Low-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape. 2016 , 196, 1964-76	30
806	The immune microenvironment of breast ductal carcinoma in situ. 2016 , 29, 249-58	98
805	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. 2016 , 6, 446-59	147
804	Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy. 2016 , 35, 263-73	5
803	Pembrolizumab for the treatment of non-small cell lung cancer. 2016 , 16, 397-406	52
802	Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. 2016 , 48, 177-87	141
801	Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. 2016 , 22, 2177-82	92
800	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. 2016 , 2, 46-54	527
799	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. 2016 , 387, 1540-1550	3964
798	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. 2016 , 13, 228-41	429
797	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. 2016 , 12, 57-75	39
796	Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. 2016 , 76, 227-38	423

795	Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). 2016 , 7, 17-39	7
794	Novel therapeutic targets in advanced urothelial carcinoma. 2016 , 98, 106-15	33
793	Checkpoint Blockade for the Treatment of Advanced Melanoma. 2016 , 167, 231-50	33
792	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. 2016 , 17, 263-270.e2	82
791	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. 2016 , 5, e1100789	36
790	Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. 2016 , 27, 1190-8	109
789	Monocyte and interferon based therapy for the treatment of ovarian cancer. 2016 , 29, 109-15	15
788	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. 2016 , 22, 3915-23	73
787	TGF β Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. 2016 , 76, 2525-39	110
786	Combining Epigenetic and Immunotherapy to Combat Cancer. 2016 , 76, 1683-9	190
785	Principles of immunotherapy. 2016 , 134, 163-81	7
784	PD-1 function in apoptosis of T lymphocytes in canine visceral leishmaniasis. 2016 , 221, 879-88	28
783	Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. 2016 , 21, 608-17	60
782	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. 2016 , 130, 25-74	119
781	CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1. 2016 , 22, 3571-81	132
780	The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target. 2016 , 12, 595-600	8
779	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. 2016 , 93, 9-16	23
778	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. 2016 , 16, 655-74	15

777	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. 2016 , 11, 469-77	31
776	Targeting the tumour microenvironment in ovarian cancer. 2016 , 56, 131-143	69
775	Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1. 2016 , 196, 2870-8	16
774	Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. 2016 , 52, 9-18	68
773	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. 2016 , 29, 285-296	227
772	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. 2016 , 21, 462-73	190
771	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. 2016 , 468, 511-25	172
770	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. 2016 , 11, 524-36	32
769	Motolimod effectively drives immune activation in advanced cancer patients. 2016 , 5, e1126037	7
768	Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. 2016 , 4, 452-62	62
767	Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. 2016 , 34, 171-81	31
766	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. 2016 , 387, 1909-20	2308
765	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. 2016 , 34, 1510-7	509
764	Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. 2016 , 64, 1274-82	43
763	Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. 2016 , 29, 528-41	42
762	Vaccines for established cancer: overcoming the challenges posed by immune evasion. 2016 , 16, 219-33	449
761	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. 2016 , 48, 194-202	13
760	Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. 2016 , 27, 1135-1137	112

759	Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma. 2016 , 37, 7583-7	5
758	Accumulation of CD5CD19 B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils. 2016 , 16, 503-509	6
757	Dendritic cells in brain diseases. 2016 , 1862, 352-67	35
756	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. 2016 , 11, 345-51	48
755	Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. 2016 , 79, 371-7	10
754	PD-1 expression conditions T cell avidity within an antigen-specific repertoire. 2016 , 5, e1104448	38
753	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. 2016 , 22, 1969-77	128
752	Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. 2016 , 16, 5-12	12
751	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. 2016 , 9, 123-35	2
750	PD-1 expression on dendritic cells suppresses CD8 T cell function and antitumor immunity. 2016 , 5, e1085146	90
749	Immune checkpoint inhibitors: a new frontier in bladder cancer. 2016 , 34, 49-55	11
748	Novel immunotherapies in lymphoid malignancies. 2016 , 13, 25-40	172
747	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. 2016 , 1865, 58-71	43
746	Immunotherapy and tumor microenvironment. 2016 , 370, 85-90	164
745	Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. 2016 , 24, 166-74	133
744	Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status. 2016 , 23, 694-702	108
743	From T cell "exhaustion" to anti-cancer immunity. 2016 , 1865, 49-57	13
742	Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. 2016 , 19, 82-92	193

741	Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer. 2017 , 36, 618-627	23
740	Function of PD-L1 in antitumor immunity of glioma cells. 2017 , 24, 803-807	16
739	Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?. 2017 , 105, 49-51	7
738	Elements of cancer immunity and the cancer-immune set point. 2017 , 541, 321-330	2136
737	COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. 2017 , 114, 1117-1122	237
736	PD-L1, Galectin-9 and CD8 tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. 2017 , 6, e1273309	93
735	Comprehensive screening for PD-L1 expression in thyroid cancer. 2017 , 24, 97-106	73
734	Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. 2017 , 13, 195-207	381
733	Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer. 2017 , 108, 81-90	35
732	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. 2017 , 114, E970-E979	124
731	Induction of B7-H1 receptor by bacterial cells fractions of Porphyromonas gingivalis on human oral epithelial cells: B7-H1 induction by Porphyromonas gingivalis fractions. 2017 , 222, 137-147	13
730	A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. 2017 , 6, 3	44
729	Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. 2017 , 96, 919-927	16
728	Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?. 2017 , 29, 207-217	5
727	Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. 2017 , 15, 1063-1070	58
726	Allergy reduces the risk of meningioma: a meta-analysis. 2017 , 7, 40333	5
725	Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. 2017 , 5, 157-169	26
724	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. 2017 , 129, 1380-1388	167

723	T cell exhaustion: from pathophysiological basics to tumor immunotherapy. 2017 , 15, 1	116
722	Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. 2017 , 23, 436-443	35
721	Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer. 2017 , 23, 3585-3591	215
720	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. 2017 , 5, 106-117	162
719	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. 2017 , 10, 34	63
718	Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. 2017 , 11, 358-372	31
717	Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. 2017 , 8, 14572	191
716	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. 2018 , 9, 14922-14938	21
715	Intratumoral administration of mRNA encoding a fusokine consisting of IFN- γ and the ectodomain of the TGF- β receptor II potentiates antitumor immunity. 2014 , 5, 10100-13	53
714	Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma. 2018 , 9, 20034-20047	23
713	Increased PD-L1 expression in radioresistant HNSCC cell lines after irradiation affects cell proliferation due to inactivation of GSK-3 β . 2019 , 10, 573-583	13
712	B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. 2015 , 6, 3452-61	81
711	Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. 2015 , 6, 9612-26	125
710	Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. 2015 , 6, 11139-49	72
709	Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. 2015 , 6, 24990-5002	38
708	Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. 2015 , 6, 40836-49	84
707	Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. 2016 , 7, 8944-55	46
706	Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. 2016 , 7, 10332-44	38

705	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. 2016 , 7, 15901-14	101
704	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. 2016 , 7, 33350-62	45
703	Melanoma immunotherapy dominates the field. 2016 , 4, 269	14
702	Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma. 2020 , 12, 7553-7560	2
701	Immunotherapy in patients with autoimmune disease. 2020 , 12, 7032-7038	7
700	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. 2020 , 27, 2402-2448	6
699	Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments. 2019 , 26, 5244-5261	4
698	Role of Regulatory Oncogenic or Tumor Suppressor miRNAs of PI3K/AKT Signaling Axis in the Pathogenesis of Colorectal Cancer. 2018 , 24, 4605-4610	14
697	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. 2017 , 18, 315-331	32
696	The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice. 2019 , 19, 632-664	4
695	Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. 2019 , 14, 100-112	11
694	Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?. 2019 , 19, 222-228	3
693	Stimulation of human CD4+ T lymphocytes via TLR3, TLR5 and TLR7/8 up-regulates expression of costimulatory and modulates proliferation. 2009 , 3, 1-8	15
692	Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia. 2017 , 18, 2269-2274	20
691	Antigen-specific immunotherapy for ovarian cancer. 2012 , 136-154	1
690	Immunomodulatory effects of Tim-3 and PD-1 on chronic hepatitis B virus infection. 2018 , 7, 6-11	1
689	Cancer vaccine development: designing tumor cells for greater immunogenicity. 2010 , 15, 309-20	1
688	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. 2020 , 8, 9-22	4

687	Epithelial-Mesenchymal Transition: Role in Cancer Progression and the Perspectives of Antitumor Treatment. 2020 , 12, 4-23	4
686	Combinations using checkpoint blockade to overcome resistance. 2020 , 14, 1148	6
685	Pembrolizumab Induces an Unexpected Conformational Change in the CC'-loop of PD-1. 2020 , 13,	1
684	Exosomes: Their Role in Pathogenesis, Diagnosis and Treatment of Diseases. 2020 , 13,	14
683	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. 2020 , 12,	8
682	Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions. 2020 , 21,	3
681	Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells. 2020 , 28, 467-481	6
680	Hepatoma cells up-regulate expression of programmed cell death-1 on T cells. 2008 , 14, 6853-7	8
679	B7 molecule mRNA expression in colorectal carcinoma. 2005 , 11, 5655-8	10
678	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. 2016 , 22, 748-63	11
677	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. 2016 , 22, 8389-8397	19
676	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. 2018 , 24, 2686-2697	15
675	Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. 2019 , 25, 1684-1696	18
674	Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. 2020 , 26, 3737-3749	8
673	[Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for ?non-small cell lung cancer]. 2014 , 17, 734-40	4
672	Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy. 2020 , 19, 3150-3158	4
671	PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer. 2020 , 19, 1223-1234	7
670	MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. 2020 , 20, 317	3

669	Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer. 2021 , 21, 10	5
668	Rheumatic complications in cancer patients treated with immune checkpoint inhibitors. 2019 , 34, 1197-1209	6
667	Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. 2014 , 26, 104-11	80
666	Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. 2015 , 7, 462-70	88
665	Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. 2015 , 6, 561-9	49
664	Immunotherapy in lung cancer. 2014 , 3, 53-63	43
663	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. 2015 , 4, 728-42	40
662	Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. 2015 , 4, 743-51	24
661	Cancer stem cells and immunoresistance: clinical implications and solutions. 2015 , 4, 689-703	69
660	Immune checkpoint inhibitors: therapeutic advances in melanoma. 2015 , 3, 267	40
659	Targeted therapies in development for non-small cell lung cancer. 2013 , 12, 22	58
658	Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens. 2018 , 15, 29	14
657	Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting. 2020 , 9, 4086-4091	2
656	Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma. 2018 , 52, 9-13	11
655	Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. 2016 , 48, 527-36	90
654	Synergistic anti-liver cancer effects of curcumin and total ginsenosides. 2020 , 12, 1091-1103	7
653	Anti program death-1/anti program death-ligand 1 in digestive cancers. 2015 , 7, 95-101	39
652	Current systemic treatment of hepatocellular carcinoma: A review of the literature. 2015 , 7, 1412-20	44

651	Immunobiology of hepatocarcinogenesis: Ways to go or almost there?. 2016 , 7, 242-55	10
650	Current status of cancer immunotherapy. 2014 , 10, 8-13	14
649	Progress in immunotherapy for small cell lung cancer. 2020 , 11, 370-377	2
648	Targeted immunotherapy for non-small cell lung cancer. 2014 , 5, 39-47	7
647	Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. 2015 , 5, 1	3
646	Cancer immunotherapy by targeting immune checkpoint receptors. 2018 , 8, 1-11	4
645	The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. 2014 , 33, 421-33	8
644	Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. 2020 , 18, 899-906	15
643	Design of PD-L1 inhibitors for lung cancer. 2019 , 15, 139-150	15
642	Comparative analysis of CD4+ and CD8+ T cells in tumor tissues, lymph nodes and the peripheral blood from patients with breast cancer. 2015 , 19, 35-44	17
641	Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity. 2012 , 13, 4031-6	38
640	IL-12 regulates B7-H1 expression in ovarian cancer-associated macrophages by effects on NF- κ B signalling. 2014 , 15, 5767-72	17
639	Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance. 2014 , 15, 1321-6	34
638	Assays for predicting and monitoring responses to lung cancer immunotherapy. 2015 , 12, 87-95	33
637	Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. 2015 , 12, 79-86	22
636	Advances in immunotherapy for treatment of lung cancer. 2015 , 12, 209-22	41
635	The effects of age and systemic metabolism on anti-tumor T cell responses. 2020 , 9,	11
634	Progranulin/GP88, A Complex and Multifaceted Player of Tumor Growth by Direct Action and via the Tumor Microenvironment. 2021 , 1329, 475-498	2

633	The New Frontier in Medicine at the Convergence of Nanotechnology and Immunotherapy. 2021 , 3-27	
632	[Angiomatoid fibrous histiocytoma: a literature review and a report of two cases]. 2021 , 83, 31-38	
631	The Serendipity of Viral Trans-Neuronal Specificity: More Than Meets the Eye. 2021 , 15, 720807	1
630	Long-Term Favorable Outcome With Nivolumab in a Case of Advanced Non-Small Cell Lung Cancer: A Case Report. 2021 , 13, e18526	
629	Case Report: Pulmonary Metastases From Epithelioid Sarcoma in Extremity Favourably Responding to Immunotherapy With Camrelizumab. 2021 , 11, 728437	1
628	Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?. 2021 , 1	0
627	Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. 2021 , 9, 760211	0
626	Mechanisms of immune checkpoint inhibitor-mediated liver injury.. 2021 , 11, 3727-3739	5
625	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. 2021 , 21, 1355-1370	1
624	Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. 2021 , 9, 72	8
623	A novel pyroptosis-associated gene signature for immune status and prognosis of cutaneous melanoma. 2021 , 9, e12304	4
622	Diagnostic Role of Extracellular Vesicles in Cancer: A Comprehensive Systematic Review and Meta-Analysis. 2021 , 9, 705791	2
621	Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. 2021 , 19, 415	2
620	Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study. 2021 , 1	2
619	Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma. 2021 , 12, 728750	1
618	Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice. 2021 , 11,	3
617	Uncovering the Immunoregulatory Function and Therapeutic Potential of the PD-1/PD-L1 Axis in Cancer. 2021 , 81, 5141-5143	1
616	A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody. 2021 , 240, 137-148	2

615 Gene-Modified Tumor-Cell Vaccines. **2004**, 253-273

614 Cancer-Specific Vaccines. **2008**, 649-669

613 Klinische Bedeutung und therapeutisches Potential des programmierten Zelltod 1- und 2-Liganden (PDL-1, L-2) fñ das kolorektale Karzinom. **2008**, 97-98

612 Cancer and the Cellular Immune Response. **2008**, 635-647

611 Development of Vaccine Therapy for Pancreas Cancer. **2008**, 683-704

610 EFFECTS OF CANCER IMMUNOTHERAPY REGIMENS ON PRIMARY VERSUS SECONDARY IMMUNE RESPONSES AND THE POTENTIAL IMPACT ON LONGTERM ANTI-TUMOR RESPONSES. **2009**, 81-89

609 New Approaches for Optimizing Melanoma Vaccines. **2008**, 143-160

608 Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma. **2009**, 367-403

607 Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer. **2009**, 575-590

606 New Strategies to Improve Tumor Cell Vaccine Therapy. **2009**, 117-131

605 Treg, Chemokines, and Other Small Molecules: Role in Metastasis and Its Prevention. **2009**, 263-279

604 Molecular Markers for Predicting Prognosis of Renal Cell Carcinoma. **2009**, 449-471

1

603 GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX. **2010**, 329-342

602 Ovarian Cancer Immunology and Immunotherapy. **2011**, 203-221

601 Immunomodulatory Functions of Cancer Stem Cells. **2012**, 301-332

600 Modulating the Tumor Microenvironment. **2012**, 353-369

599 Cell Surface Co-signaling Molecules in the Control of Innate and Adaptive Cancer Immunity. **2012**, 251-266

598 Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies. **2012**, 291-306

- 597 T-cell Immune Abnormality and Novel Immunotherapeutic Approach by Blocking the B7-H1-PD-1 Pathway Combined with WT1 Tumor Vaccine in Myelodysplastic Syndromes. **2012**, 79, 93-94
- 596 Development of Novel Anti-Cancer Immunotherapy Targeting Immune Evasion Mechanisms. **2012**, 61, 5-10 1
- 595 Activation of Immune-Mediated Tumor Cell Death by Chemotherapy. **2013**, 373-399
- 594 Signaling of Tumor-Induced Immunosuppression of Dendritic Cells. **2013**, 339-360
- 593 Cancer immunotherapy with blocking of immune checkpoints. **2013**, 125, 13-18
- 592 MHC Class I Antigens and the Tumor Microenvironment. **2013**, 253-286
- 591 Emerging Targeted Agents for HER2-Positive Breast Cancer. **2013**, 75-96
- 590 Overview of MHC Class I Antigens. **2013**, 1-11
- 589 Tumours: Immunotherapy.
- 588 The Cancer Super-Chaperone Hsp90: Its Posttranslational Regulation and Drug Targeting. **2013**, 253-270
- 587 Immunotherapy in Renal Cell Carcinoma. **2014**, 125-147
- 586 Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer. **2014**, 435-462
- 585 Immune Response: Glioma-Associated Immunosuppression. **2014**, 221-239
- 584 Rabies: Neurobiology. **2014**, 251-267
- 583 Overcoming Cancer Tolerance with Immune Checkpoint Blockade. **2015**, 87-129
- 582 Emerging Biomarkers During Clinical Development of Anti-CTLA4 Antibody Therapy. **2015**, 427-439
- 581 Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy. **2015**, 191-209
- 580 T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy. **2015**, 211-229

- 579 The Multifaceted Role of PD-1 in Health and Disease. **2016**, 441-457
- 578 New Treatments for Advanced Melanoma. **2016**, 78, 5-12
- 577 Emerging targeted agents for HER2-positive breast cancer. **2016**, 87-110
- 576 Translational Research and Immunotherapy in Lung Cancer. **2016**, 255-296
- 575 Vascular Normalization, T Cell Trafficking and Anti-tumor Immunity. **2016**, 51-76
- 574 T cell co-stimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. ○
- 573 A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. **2017**, 5, 1-5
- 572 Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer. **2017**, 13, 131-137
- 571 Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer. **2017**, 1, 152-158
- 570 New Development of Cancer Immunotherapy : History of Immunity Check Inhibitors Focusing on Programmed Death-1 (PD-1). **2018**, 27, 712-722
- 569 Immunotherapy in the drug treatment of patients with triple-negative metastatic breast cancer. **2018**, 7, 60
- 568 B7-H1(PD-L1) confers chemoresistance through ERK and p38 MAPK pathway in tumor cells. 2
- 567 Implications of the HDAC6-ERK1 feed-forward loop in immunotherapy. **2018**, 2, 59-68 1
- 566 PD-L1 and Immunotherapy in Patients with Non-Small Cell Lung Cancer and Malignant Pleural Effusion. **2018**,
- 565 Immune Checkpoint Inhibitors in the Treatment of Lymphomas. **2018**, 11, 303-312 7
- 564 Treatment of Advanced Pancreatic Carcinoma. **2019**, 255-268
- 563 Innate and Adaptive Immune Responses to Cancer. **2019**, 111-159 1
- 562 Expressions and Clinical Significance of PD-L1 and PD-1 in Prostate Cancer. **2019**, 08, 9-14

- 561 Development of Human Neuroblastomas in Mouse-Human Neural Crest Chimeras.
- 560 Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. **2019**, 1-24
- 559 Immunology of Melanoma. **2019**, 1-32
- 558 Hepatocellular Carcinoma. **2019**, 207-234
- 557 The Expression of CD155 on Renal Cell Carcinoma Cells. **2019**, 09, 373-381
- 556 Mechanism of resistance to immune checkpoint inhibitors.. **2019**, 2, 178-188 2
- 555 A new strategy for fighting cancer, or how the Brake of the immune system works. **2019**, 44-57
- 554 [Chemotherapy-Free Treatment of Hematological Neoplasias: Dream or Reality?]. **2019**, 108, 411-418
- 553 Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy. **2019**, 19, 449-467 5
- 552 Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review. **2019**, 12, 9663-9668
- 551 Esophageal and Gastric Cancer. **2020**, 31-46
- 550 Immunopathology and Immunotherapy of Melanoma. **2020**, 305-332
- 549 Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. **2020**, 1141-1164
- 548 Effects of combined treatment with PD-L1 Ig and CD40L mAb on immune tolerance in the CBA/J x DBA/2 mouse model. **2020**, 21, 1789-1798 2
- 547 Expression of Toll like Receptor 4 in the ductal epithelial cells of the Breast tumor microenvironment is correlated with the invasiveness of the tumor.
- 546 Combination of pembrolizumab and I attenuates the aggressiveness of non-small cell lung cancer. **2020**, 19, 4142-4150
- 545 In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. **2020**, 111, 1887-1898 2
- 544 PD-L1 glycosylation and its impact on binding to clinical antibodies.

543	The Recent Advances of Anti-PD-1/PD-L1 Immunotherapy. 2020 ,	
542	Classic articles in Apoptotic Research: A Bibliometric Analysis.	
541	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. 2021 , 85-128	
540	Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. 2021 , 11,	4
539	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia. 2021 , 14,	1
538	The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens. 2021 , 100043	2
537	Biological Therapies in the Treatment of Cancer-Update and New Directions. 2021 , 22,	2
536	CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses. 2021 , 131,	3
535	Synergy between type I Immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. 2021 , 9,	5
534	Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. 2021 , 101, 108322	5
533	Pancreatic Tumor Microenvironment. 2020 , 1296, 243-257	1
532	Immunology of Melanoma. 2020 , 41-72	
531	Dynamic regulation of hierarchical heterogeneity in Acute Myeloid Leukemia serves as a tumor immunoevasion mechanism.	
530	Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN- β Signaling. 2020 , 20, 868-874	1
529	B4GALNT1 promotes progression and metastasis in lung adenocarcinoma through JNK/c-Jun/Slug pathway. 2021 , 42, 621-630	3
528	Transcriptional analysis of immune modulatory genes in melanoma treated with PD-1 blockade.	0
527	An Overview of Promising Biomarkers in Cancer Screening and Detection. 2020 , 20, 831-852	1
526	A dual promoter system to monitor IFN- β signaling in vivo at single-cell resolution. 2021 ,	0

- 525 Research on Cervical Cancer and Its Drug Treatment. **2020**, 185, 03041
- 524 Synergy of Immunotherapy and Radiosurgery. **2020**, 355-369
- 523 Cancer Stem Cells and the Development of Cancer. **2020**, 151-192
- 522 Targeting the Immune System in Pancreatic Cancer. **2020**, 203-218
- 521 Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. **2020**, 41-68
- 520 Screening and Identification of a Novel Anti-siglec-15 Human Antibody 3F1 and the Research on Its Antitumor Activity.
- 519 Reacci3 liquenoide oral ulcerada secundaria al uso de pembrolizumab. **2020**, 35, 173-175
- 518 Immunotherapy for Glioblastomas.
- 517 The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis. **2021**, 11, 21504 2
- 516 Different transcriptomic architecture of the gill epithelia in Nile and Mozambique tilapia after salinity challenge. **2021**, 41, 100927 0
- 515 The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma.. **2021**, 28, 4542-4551 0
- 514 Moving towards the Future of Radio-Immunotherapy: Could We Tailor the Abscopal Effect on Head and Neck Cancer Patients?. **2021**, 1, 410-423
- 513 PD-1 and PD-L1 Expression in Indian Women with Breast Cancer.. **2022**, 18, 21-29 2
- 512 SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.
- 511 Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma. **2021**, 12, 721409 2
- 510 Programmed Cell Death Ligand 1 Is Enriched in Mammary Stem Cells and Promotes Mammary Development and Regeneration. **2021**, 9, 772669 1
- 509 Blockade or deficiency of PD-L1 expression in intestinal allograft accelerates graft tissue injury in mice. **2021**, 0
- 508 Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples. **2021**, 18, 28 0

- 507 Multiplexed immunofluorescence identifies high stromal CD68PD-L1 macrophages as a predictor of improved survival in triple negative breast cancer. **2021**, 11, 21608 3
- 506 PD-L1-expressing astrocytes act as a gate-keeper for neuroinflammation in the central nervous system of mice with traumatic brain injury. 0
- 505 Immunosuppression Induced by Glutamine Deprivation Occurs Activating PD-L1 Transcription in Bladder Cancer. **2021**, 8, 687305 0
- 504 A versatile platform for the tumor-targeted delivery of immune checkpoint-blocking immunoglobulin G. **2021**, 340, 243-258 0
- 503 Regulation of specific cell clusters in TCR-T cells responding to differential expression of tumor PD-L1.
- 502 Single-cell transcriptome analysis of the immunosuppressive effect of differential expression of tumor PD-L1 on responding TCR-T cells.
- 501 Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy. **2020**, 016-018
- 500 CD137/CD137 Ligand in Tumor and Viral Immunotherapy. **2006**, 117-135
- 499 B7 Family Molecules in the Placenta. **2006**, 159-170
- 498 Contribution of B7-H1/PD-1 Co-inhibitory Pathway to T-Cell Dysfunction in Cancer. **2008**, 29-40
- 497 Checkpoint Blockade and Combinatorial Immunotherapies. **2007**, 363-390
- 496 T Cells and Antigen Recognition. **2007**, 33-53
- 495 Immunomodulatory Molecules of the Immune System. **2007**, 67-121
- 494 Tumor Immune Escape Mechanisms. **2006**, 577-602 1
- 493 PD-L1 lncRNA splice promotes lung adenocarcinoma progression via enhancing c-Myc activity.
- 492 Molecular portrait of stomach cancer associated with the EpsteinBarr virus. **2020**, 7, 27-36
- 491 Role of Growth factors (HB-EGF, VEGF-A) and Immunotolerance Mediators (TNF- β , FN- β , PD-L1 and IL-10) in Acute and Chronic Otitis Media.
- 490 Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. **2006**, 3, 179-87 58

489	Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. 2009 , 9, 3	125
488	Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. 2011 , 84, 409-21	90
487	Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. 2012 , 18, 153-9	23
486	Increased B7-H1 and B7-H4 Expressions on Circulating Monocytes and Tumor-Associated Macrophages are Involved in Immune Evasion in Patients with Gastric Cancer. 2011 , 54, 1-10	18
485	T cell costimulation and coinhibition: genetics and disease. 2011 , 12, 119-28	16
484	Reflections on immune checkpoint inhibition in non-small cell lung cancer. 2014 , 3, 411-3	9
483	Correlation study of Bcl-2, B7-H1, EGFR, VEGF and colorectal cancer. 2015 , 5, 2277-84	5
482	Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. 2015 , 8, 9351-9	21
481	Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. 2015 , 8, 11084-91	62
480	Shedding light on the molecular determinants of response to anti-PD-1 therapy. 2015 , 4, 816-9	17
479	PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. 2016 , 4, 1-8	20
478	Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis. 2016 , 8, 516-29	17
477	Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. 2016 , 8, 3274-87	33
476	B7-H3 role in the immune landscape of cancer. 2017 , 6, 66-75	90
475	[A Reflection of the New Wave of Immunotherapy on the Clinical Study of ?Chinese Lung Cancer Immunotherapy]. 2017 , 20, 695-702	0
474	[Advances of immunotherapy in small cell lung cancer]. 2014 , 17, 474-80	
473	Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. 2018 , 8, 1307-1316	42
472	Advances in the systemic treatment of metastatic melanoma. 2013 , 27, 374-81	3

471	Immune mechanisms of idiosyncratic drug-induced liver injury. 2017 , 3, 145-156	15
470	Therapeutic targeting of immune checkpoints with small molecule inhibitors. 2019 , 11, 529-541	8
469	Immune reaction by cytoreductive prostatectomy. 2019 , 7, 64-79	2
468	Type I phosphatidylinositol phosphate kinase dependent cell migration and invasion are dispensable for tumor metastasis. 2019 , 9, 959-974	1
467	Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer. 2019 , 18, 2661-2669	2
466	[Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC]. 2019 , 22, 512-519	0
465	[Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors]. 2019 , 22, 786-793	
464	Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines. 2019 , 12, 123-132	4
463	High level of programmed death ligand 1 (PD-L1) predicts longer survival in patients with resectable small cell lung cancer. 2018 , 11, 2675-2682	3
462	The prognostic significance of pdl1 and foxp3 expressions in tumor cells and the tumor microenvironment of ovarian epithelial tumors. 2018 , 11, 3884-3890	
461	Programmed death ligand 1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features. 2017 , 10, 10565-10570	
460	Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis. 2017 , 10, 11754-11759	1
459	Experimental model for the irradiation-mediated abscopal effect and factors influencing this effect. 2020 , 10, 440-453	6
458	[Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma]. 2020 , 38, 449-453	1
457	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. 2017 , 15, 466-477	3
456	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. 2017 , 15, 543-551	4
455	MicroRNAs and their role in immunogenetic-dysregulation. 2022 , 193-225	
454	Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy.. 2021 , 86, 1461-1468	0

453	PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage. 2021 , 118,	2
452	Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer. 2021 , 11, 766248	2
451	Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer. 2021 ,	5
450	 PD-1/PD-L1-  2021 , 86, 1677-1686	
449	A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer.. 2021 , 11,	1
448	Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients. 2021 , 13,	1
447	GOLM1 exacerbates CD8 T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. 2021 , 6, 397	1
446	Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. 2021 , 12, 6742	6
445	Acidic and Hypoxic Microenvironment in Melanoma: Impact of Tumour Exosomes on Disease Progression.. 2021 , 10,	2
444	Immune Tolerance in the Oral Mucosa. 2021 , 22,	1
443	Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma. 2021 , 13, 1725-1740	1
442	Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. 2021 , 40, 102492	0
441	Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression.. 2021 , 95, 153867	0
440	Fractional Laser Treatment Boosts Systemic Anti-Tumor Immunity in Combination with OX40 Agonist and PD-1 Blockade.	
439	Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.. 2021 , 12, 790661	1
438	Landscape of Immunotherapy in Genitourinary Malignancies.. 2021 , 1342, 143-192	0
437	Drug discovery is an eternal challenge for the biomedical sciences. 2022 , 1, 1-3	4
436	Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.. 2022 , 236, 108106	3

435	The changing clinical spectrum of endocrine adverse events in cancer immunotherapy.. 2021 ,	4
434	Biomarkers for Immunotherapy in Gastrointestinal Cancers. 2021 ,	
433	Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review.. 2021 , 15, 497	0
432	Signal pathways of melanoma and targeted therapy.. 2021 , 6, 424	5
431	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.. 2022 , 11,	4
430	Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.. 2022 ,	12
429	Novel Risk Classification Based on Pyroptosis-Related Genes Defines Immune Microenvironment and Pharmaceutical Landscape for Hepatocellular Carcinoma.. 2022 , 14,	0
428	Tumor-endogenous PD-1 promotes cell proliferation and predicts poor survival in non-small cell lung cancer.. 2022 , 11, 3-13	0
427	Targeting transforming growth factor- β by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer.. 2022 , 1	0
426	In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-1/PD-L1 interaction.. 2022 , 12, 303	0
425	Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling.. 2022 ,	0
424	lLncRNA IFITM4P is activated through LPS/TLR4 and promotes immune escape by up-regulating PD-L1 via dual mechanism during oral carcinogenesis.. 2022 ,	5
423	Preoperative Immune Checkpoint Inhibition and Cryoablation in Early-Stage Breast Cancer.	
422	The Clinical, Pathological, and Prognostic Value of High PD-1 Expression and the Presence of Epstein-Barr Virus Reactivation in Patients with Laryngeal Cancer.. 2022 , 14,	
421	A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.. 2022 , 29, 2072-2084	
420	Fatty acid synthetase expression in triple-negative breast cancer.. 2022 ,	1
419	Expression of PD-L1 and CD4+ tumor-infiltrating lymphocytes predict survival in head and neck squamous cell carcinoma.. 2022 , 16, 59	0
418	Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions.. 2022 , 23,	6

417	Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells Vav1-Dependent NF- κ B Disinhibition.. 2022 , 12, 747482	0
416	Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias.. 2022 , 11,	1
415	Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γ T cells.. 2022 , 13, 231	2
414	Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance anti-HIV activity in vitro.	0
413	Differential expression of inhibitory receptor NKG2A distinguishes disease-specific exhausted CD8 T cells.. 2022 , 3, e111	
412	Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polarization.. 2022 , 20, 12	2
411	ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression.. 2022 ,	2
410	Tumors resurrect an embryonic vascular program to escape immunity.. 2022 , 7, eabm6388	0
409	PD-L1 Overexpression Correlates with JAK2-V617F Mutational Burden and Is Associated with 9p Uniparental Disomy in Myeloproliferative Neoplasms.. 2022 ,	1
408	Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.. 2022 ,	2
407	Programmed cell death 1 ligand 1 signals in cancer cells.. 2022 ,	12
406	Novel Mouse Models for Cancer Immunology. 2022 , 6,	0
405	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1.. 2021 , 12, 806043	1
404	Identification of a Four-Gene Signature Associated with the Prognosis Prediction of Lung Adenocarcinoma Based on Integrated Bioinformatics Analysis.. 2022 , 13,	1
403	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.. 2022 , 1	
402	PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF- β receptor I versus II.. 2022 , 38, 110349	0
401	Immune checkpoint inhibitors for the treatment of melanoma.. 2022 , 1-14	1
400	Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms.. 2022 , 1	

399	PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury.. 2022 , 19, 43	2
398	Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6.. 2022 , 39, 278-286	1
397	Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy.. 2022 , 106, 108617	0
396	Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer.. 2022 , 106, 108561	0
395	Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment.. 2021 , 6, 422	3
394	Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.	
393	A New Standard of Care: Pembrolizumab in Programmed Death-ligand 1 Positive, Metastatic, Triple-negative Breast Cancer. 2021 , 17, 60	
392	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.. 2022 , 22, e2	8
391	Immunotherapeutic approaches for HPV-caused cervical cancer.. 2022 , 129, 51-90	
390	Effects of PD-1 Signaling on Immunometabolic Reprogramming.. 2022 , 4,	0
389	Interlocked feedback loops balance the adaptive immune response.. 2022 , 19, 4084-4100	
388	Teaching cancer imaging in the era of precision medicine: Looking at the big picture.. 2022 , 9, 100414	0
387	Investigation of Unprecedented Sites and Proposition of New Ligands for Programmed Cell Death Protein 1 through Molecular Dynamics with Probes and Virtual Screening.. 2022 ,	0
386	D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.. 2022 , 119,	5
385	The Diminishment of Novel Endometrial Carcinoma-Derived Stem-like Cells by Targeting Mitochondrial Bioenergetics and MYC.. 2022 , 23,	
384	Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway.. 2022 , 2022, 4598573	0
383	Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation.. 2022 ,	5
382	The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.. 2022 , 14,	0

381	Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study.. 2022 , 12, 820302	1
380	Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer.. 2022 , 14,	0
379	Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance.. 2021 , 9, 762029	1
378	PDL1 positivity rate between triple negative and non-luminal Her2+ cases. 2022 , 18,	
377	Prognostic value of CD155/TIGIT expression in patients with colorectal cancer.. 2022 , 17, e0265908	1
376	TGF- β -Mediated PD-L1 Glycosylation Contributes to Immune Escape c-Jun/STT3A Pathway in Nasopharyngeal Carcinoma.. 2022 , 12, 815437	0
375	MMP-responsive transformation nanomaterials with IAP antagonist to boost immune checkpoint therapy.. 2022 , 343, 765-776	0
374	Tetraspanin CD9: A friend or foe of head and neck cancer (Review).. 2022 , 47,	0
373	The ITPRIPL1- CD3 β axis: a novel immune checkpoint controlling T cells activation.	
372	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.. 2022 , 13, 827921	4
371	The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.. 2022 , 1	0
370	CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity.. 2022 , 13, 1606	7
369	Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. 2022 , 212761	
368	Characterization of the Different Subtypes of Immune Cell Infiltration to Aid Immunotherapy.. 2021 , 9, 758479	
367	A novel PD-L1-targeted shark V single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer.. 2022 , 24, 849-863	2
366	Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances.. 2022 , 14,	1
365	Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.. 2022 , 1	1
364	LncRNA NEAT1 regulate diffuse large B-cell lymphoma by targeting miR-495-3p/PD-L1 axis.. 2022 , 1-8	0

363	Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.. 2022 , 23,	1
362	Efficacy and Prognostic Factors for Response to PD-1 Inhibitors in Advanced Cervical Carcinoma: A Retrospective Study.. 2022 , 16, 887-897	2
361	Targeting HIF-1 α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues.. 2022 ,	6
360	eEF2K promotes PD-L1 stabilization through inactivating GSK3 β in melanoma.. 2022 , 10,	0
359	PD-1 and PD-L1 expression in mycosis fungoides and Sjögren Syndrome.. 2022 ,	
358	High Expression of RAI14 in Triple-Negative Breast Cancer Participates in Immune Recruitment and Implies Poor Prognosis Through Bioinformatics Analyses.. 2022 , 13, 809454	1
357	Treatment of Recurrent and Metastatic HPV-Associated Squamous Cell Carcinoma. 1	
356	Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy.. 2022 , 13, 838966	0
355	Overexpression of PD-L1 causes germ cells to slough from mouse seminiferous tubules via the PD-L1/PD-L1 interaction.. 2022 ,	0
354	Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts.. 2022 , 10,	1
353	Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.. 2022 , 13, 1898	0
352	Networks of CD8 T Cell Response Activation in Melanoma and Vitiligo.. 2022 , 13, 866703	0
351	Proteomic tools for the quantitative analysis of artificial peptide libraries: detection and characterization of target-amplified PD-1 inhibitors.. 2022 ,	0
350	Knocking down Siglec-15 in osteosarcoma cells inhibits proliferation while promoting apoptosis and pyroptosis by targeting the Siglec-15/STAT3/Bcl-2 pathway.. 2022 , 67, 187-195	0
349	Research trends of immune checkpoint blockade in melanoma: a visualization and bibliometric analysis (Preprint).	0
348	Formation of necrotizing vasculitis in the patient with diffuse B-cell large cell lymphoma on immune checkpoint inhibitor (PD-1) therapy. 2021 , 13, 83-90	
347	Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.. 2021 , 16, e0257972	1
346	Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. 2021 , 12, 7041	5

345	Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.. 2021 , 12, 756282	0
344	CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates.. 2021 , 11, 744107	3
343	Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression. 2021 ,	2
342	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.. 2021 , 12, 793831	2
341	Enhancer RNA-based modeling of adverse events and objective responses of immunotherapy.	
340	An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.. 2021 , 9,	6
339	Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. 2021 ,	0
338	The foundations of immune checkpoint blockade and the ipilimumab approval decennial.. 2021 ,	15
337	A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract.. 2022 , 28, e935348	0
336	The Effects of Moxibustion on PD-1/PD-L1-Related Molecular Expression and Inflammatory Cytokine Levels in RA Rats. 2021 , 2021, 1-10	
335	miR-150-5p-Containing Extracellular Vesicles Are a New Immunoregulator That Favor the Progression of Lung Cancer in Hypoxic Microenvironments by Altering the Phenotype of NK Cells.. 2021 , 13,	1
334	Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset.. 2021 , 12, 10366-10378	1
333	PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.. 2021 , 12, 762989	2
332	The Role of Exosomes in Cancer Progression.. 2021 , 23,	2
331	ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. 2021 ,	4
330	FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma.. 2021 , 11, 756843	2
329	Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy. 2021 ,	4
328	Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity. 2005 , 65, 1089-1096	365

- 327 Design, synthesis and biological evaluation of new dihydropyridine derivatives as PD-L1 degraders for enhancing antitumor immunity.. **2022**, 125, 105820 0
- 326 Monoclonal antibody Daratumumab promotes macrophage-mediated anti-myeloma phagocytic activity via engaging FC gamma receptor and activation of macrophages.. **2022**, 1
- 325 An unexpected role for PD-L1 in front-rear polarization and directional migration.. **2022**, 221,
- 324 DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion.. **2022**, 13, 2059 3
- 323 High Levels of PD-L1 and Hyal2 Myeloid-derived Suppressor Cells in Renal Cell Carcinoma.. **2022**, 9, 1-6 0
- 322 Data_Sheet_1.PDF. **2018**,
- 321 Data_Sheet_1.PDF. **2019**,
- 320 Image_1.jpeg. **2018**,
- 319 Image_3.jpeg. **2018**,
- 318 Image_4.jpeg. **2018**,
- 317 Image_5.jpeg. **2018**,
- 316 Image_6.jpeg. **2018**,
- 315 DataSheet_1.pdf. **2020**,
- 314 Table_1.docx. **2020**,
- 313 Table_2.xlsx. **2020**,
- 312 Table_3.xlsx. **2020**,
- 311 Table_4.docx. **2020**,
- 310 Table_5.xlsx. **2020**,

309 data_sheet_1.docx. **2018**,

308 Data_Sheet_1.docx. **2020**,

307 presentation_1.PDF. **2018**,

306 Data_Sheet_1.docx. **2019**,

305 Data_Sheet_1.docx. **2020**,

304 Image_1.eps. **2018**,

303 Image_2.eps. **2018**,

302 Data_Sheet_1.docx. **2019**,

301 Data_Sheet_1.PDF. **2020**,

300 Data_Sheet_1.docx. **2019**,

299 Data_Sheet_1.CSV. **2020**,

298 Data_Sheet_2.doc. **2020**,

297 Image_1.TIF. **2020**,

296 Image_2.TIF. **2020**,

295 Image_3.TIF. **2020**,

294 Image_4.TIF. **2020**,

293 Image_5.TIF. **2020**,

292 Image_6.TIF. **2020**,

291 Image_7.TIF. 2020,

290 Image_8.PNG. 2020,

289 Table_1.XLSX. 2019,

288 image_1.PDF. 2018,

287 image_2.PDF. 2018,

286 image_3.PDF. 2018,

285 image_4.PDF. 2018,

284 image_5.PDF. 2018,

283 image_6.PDF. 2018,

282 image_7.PDF. 2018,

281 image_8.PDF. 2018,

280 table_1.xlsx. 2018,

279 Image_1.JPEG. 2020,

278 Image_2.JPEG. 2020,

277 Image_3.JPEG. 2020,

276 Table_1.XLSX. 2020,

275 Table_2.XLSX. 2020,

274 Table_3.XLSX. 2020,

273	Table_4.XLSX. 2020 ,	
272	Data_Sheet_1.docx. 2018 ,	
271	Data_Sheet_1.PDF. 2019 ,	
270	Table_1.docx. 2019 ,	
269	Table_1.XLSX. 2019 ,	
268	Data_Sheet_1.pdf. 2020 ,	
267	FN3 linked nanobubbles as a targeted contrast agent for US imaging of cancer-associated human PD-L1.. 2022 ,	1
266	Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?. 2022 , 17, 592-595	
265	Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype. 2021 , 36, 77-89	
264	De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.. 2022 , 12, 123-137	1
263	Application and Research Progress of Immunosuppressive Agent-Based Systemic System Therapy in Advanced Hepatocellular Carcinoma. 2022 , 12, 3079-3086	
262	Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway. 2022 , 13, 11240-11257	0
261	Global research trends on immunotherapy in cancer: a visualization analysis (Preprint).	
260	The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value.. 2022 , 11,	0
259	The Immune Microenvironment in Gastric Cancer: Prognostic Prediction.. 2022 , 12, 836389	0
258	Over-expression of Programmed Death Ligand 1 (PD-L1) in Refractory Inflammatory Bowel Disease (IBD).. 2022 ,	0
257	Resistance Mechanisms to Anti-PD Cancer Immunotherapy.. 2022 , 40, 45-74	3
256	Advanced Materials for Management of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors. 2022 , 110738	

255	EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification and management.. 2022,	7
254	Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature. 2022, 13,	2
253	The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma. 2022, 153934	0
252	Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer.. 2022,	1
251	Gambogic acid suppresses nasopharyngeal carcinoma via rewiring molecular network of cancer malignancy and immunosurveillance. 2022, 150, 113012	1
250	Extracellular vesicles from blood of breast cancer women induce angiogenic processes in HUVECs.. 2022, 76, 101814	1
249	Penile cancer: Updates in systemic therapy. 2022,	0
248	Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT).. 2022, 1	
247	Evolution of Medical Approaches and Prominent Therapies in Breast Cancer. 2022, 14, 2450	
246	Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy.. 2022, 12, e050112	1
245	Cancer Immunoediting in the Era of Immuno-oncology.. 2022,	0
244	The role of biomarkers in personalized immunotherapy.. 2022, 10, 32	3
243	Detection of PD-L1-Expressing Myeloid Cell Clusters in the Hyaluronan-Enriched Stroma in Tumor Tissue and Tumor-Draining Lymph Nodes.. 2022,	0
242	Detection of Temozolomide-Induced Hypermutation and Response to PD-1 Checkpoint Inhibitor In Recurrent Glioblastoma.	0
241	No Time to Die: How Kidney Cancer Evades Cell Death. 2022, 23, 6198	0
240	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. 13,	1
239	Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt. 2022, 8, e09474	
238	Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis.	0

237	Genetic Variation of PD-L1 Gene Affects its Expression and Is Related to Clinical Outcome in Epithelial Ovarian Cancer. 2022 , 12,	0
236	When immunotherapy meets surgery in non-small cell lung cancer. 2022 ,	0
235	Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. 2022 , 12,	0
234	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. 2022 , 11,	0
233	L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression. 2022 , 10, e003957	0
232	Radiopharmaceuticals as Novel Immune System Tracers. 2022 , 100936	
231	Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome.	0
230	Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.	0
229	The Potential Role of Exosomal Proteins in Prostate Cancer. 12,	2
228	Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.	1
227	Tumor-immune metaphenotypes orchestrate an evolutionary bottleneck that promotes metabolic transformation.	0
226	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.	9
225	Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment. 2022 , 20,	0
224	Resveratrol in cancer treatment with a focus on breast cancer. 2022 , 15,	
223	Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF- β degradation. 2022 , 13,	2
222	Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review. 2022 , 110, 108900	3
221	Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma. 2022 , 36, 514-532	2
220	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. 2022 , 3, 665-680	0

219	Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope. 13,	2
218	Screening and Identification of A Novel Anti-Siglec-15 Human Antibody 3F1 and Relevant Antitumor Activity. MOLPHARM-AR-2021-000470	
217	CHI3L1 Enhances Melanoma Lung Metastasis via Regulation of T cell Co-stimulators and CTLA-4/B7 Axis.	
216	Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. 13,	1
215	Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis.	
214	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.	1
213	Retrospective Study of Clinical Outcomes and Toxicity Profile in Patients Treated with Immune Checkpoint Inhibitors.	
212	TLR4 signaling in presence of HIV-induced activation enhances programmed death ligand-1 expression on human plasmacytoid dendritic cells and modulates their function.	
211	Exploring immunotherapy in colorectal cancer. 2022 , 15,	5
210	Generation, secretion and degradation of cancer immunotherapy target PD-L1. 2022 , 79,	0
209	IFN γ Induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. 2022 , 97, 110400	0
208	PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition. 12,	
207	Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. 2022 , 11, 2249	1
206	The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma. 12,	
205	Current insight into the regulation of PD-L1 in cancer. 2022 , 11,	0
204	Evolving Understanding of T-cell Cosignaling Pathways. 2022 , 106, e388-e390	
203	Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients. 2022 , 10, 1827	0
202	PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy.	0

201	Recent Advances and Challenges in Cancer Immunotherapy. 2022 , 14, 3972	3
200	Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy. 2022 , 22,	2
199	A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies. 2022 , 41, 202-209	0
198	Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion.	
197	Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases. 2022 , 23, 8599	2
196	Immunohistochemical Expression of Programmed Death Ligand 1 in Oral Extranodal Diffuse Large B Cell Lymphoma.	
195	To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3. 2022 , 188783	0
194	Immunotherapeutic targets in non-small cell lung cancer.	1
193	Computational design of PD-L1 small molecule inhibitors for cancer therapy.	2
192	Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programmed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. 12,	
191	Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. 2022 , 22,	
190	Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. 2022 , 349, 844-875	2
189	A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells. 2022 , 111, 109022	
188	Therapeutic Applications of the CRISPR-Cas System. 2022 , 9, 477	0
187	Successes and failures of immunotherapy for gastric cancer. 2022 , 27, 103343	0
186	Tumor Microenvironment and Inflammatory Markers. 2022 , 35-43	0
185	SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization. 2022 , 20,	0
184	Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature. 2022 , 12, 2116	0

183	Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review). 2022 , 61,	0
182	Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. 11,	0
181	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. 2022 , 7,	5
180	Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma. 1-10	0
179	MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer. 2022 ,	1
178	Targeted therapy in NPM1-mutated AML: Knowns and unknowns. 12,	2
177	miR-uculous new avenues for cancer immunotherapy. 13,	0
176	Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma. 12,	0
175	Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy. 2022 , 10, 1552	0
174	Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. 9,	0
173	PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity. 2022 , 12, 1226	0
172	Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1. 2022 , 7,	0
171	Efficacy and Safety of the Anti-PD-L1 Monoclonal Antibody Socazolimab for Recurrent or Metastatic Cervical Cancer: A Phase I Dose-Escalation and Expansion Study.	0
170	Role of Molecular Targeted Therapeutic Drugs in Treatment of Oral Squamous Cell Carcinoma: Development and Current Strategies A Review Article. 2022 , 09, 242-246	0
169	Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.	0
168	Therapeutic strategies for gastric cancer targeting immune cells: Future directions. 13,	0
167	High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood. 2022 , 10, 2405	0
166	PD-L1 expression in lung cancer and paired brain metastases B single center study in 190 patients.. 2022 , 100413	0

- 165 Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. 13, 0
- 164 A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease. **2022**, 12, 1
- 163 NOX4 has the potential to be a biomarker associated with colon cancer ferroptosis and immune infiltration based on bioinformatics analysis. 12, 0
- 162 The new progress in cancer immunotherapy. 0
- 161 Interferon- γ induces immunosuppression in salivary adenoid cystic carcinoma by regulating programmed death ligand 1 secretion. **2022**, 14, 0
- 160 Novel treatments in optic pathway gliomas. 2, 0
- 159 Clinical significance for diagnosis and prognosis of POP1 and its potential role in breast cancer: a comprehensive analysis based on multiple databases. **2022**, 14, 6936-6956 1
- 158 Viral Agents as Potential Drivers of Diffuse Large B-Cell Lymphoma Tumorigenesis. **2022**, 14, 2105 1
- 157 Therapeutic Advances in Immunotherapies for Hematological Malignancies. **2022**, 23, 11526 0
- 156 PD-L1 antibody enhanced β -glucan antitumor effects via blockade of the immune checkpoints in a melanoma model. 0
- 155 Role of non-cardiomyocytes in anticancer drug-induced cardiotoxicity: A systematic review. **2022**, 105283 0
- 154 Molecular dynamics identifies semi-rigid domains in the PD-1 checkpoint receptor bound to its natural ligand PD-L1. 10, 0
- 153 PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression. **2022**, 13, 0
- 152 Lipid metabolic features of T cells in the Tumor Microenvironment. **2022**, 21, 0
- 151 A minimally designed PD-L1-targeted nanocomposite for positive feedback-based multimodal cancer therapy. **2022**, 1
- 150 CRISPR Activation Screening Identifies VGLL3/EAD1/BUNX1/3 as a Transcriptional Complex for PD-L1 Expression. **2022**, 209, 907-915 0
- 149 Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. **2023**, 220, 1
- 148 EBV-associated diseases: Current therapeutics and emerging technologies. 13, 1

147	Preliminary Analysis of Cervical Cancer Immunotherapy. 2022 , 45, 486-490	0
146	Targeting Both Autophagy and Immunotherapy in Breast Cancer Treatment. 2022 , 12, 966	0
145	Cancer Immunotherapy. 1-22	0
144	Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer.	2
143	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. 2022 , 23, 13241	0
142	PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. 2022 , 10, e004590	0
141	Clinical cancer immunotherapy: Current progress and prospects. 13,	2
140	Clinical implications of T cell exhaustion for cancer immunotherapy.	9
139	Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review. 2022 , 10, 1727	0
138	Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity. 2022 , 12,	0
137	Principles of Radiation Oncology. 1-10	0
136	Advances in immunotherapy for glioblastoma multiforme. 13,	0
135	Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. 2022 , 11, 3365	0
134	Programmed death-ligand 1 expression in human cancer three-dimensional cell culture models.	0
133	Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. OF1-OF13	0
132	Leverage biomaterials to modulate immunity for type 1 diabetes. 13,	0
131	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. 2022 , 58, 1572	0
130	Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma. jclinpath-2021-207795	0

- 129 The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. **2022**, 310, 121138 ○
- 128 Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. ○
- 127 Hypermethylation in the promoter region inhibits AJAP1 expression and activates the JAK/STAT pathway to promote prostate cancer cell migration and stem cell sphere formation. **2022**, 154224 ○
- 126 SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity. ○
- 125 The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity. **2022**, ○ 1
- 124 PD-L1 expression as predictor of immunotherapy eligibility in penile squamous cell carcinoma patients. 11, 1281 ○
- 123 Global research trends on immunotherapy in cancer: a visualization analysis. ○
- 122 Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis. **2022**, 29, 107327482211406 ○
- 121 Characterization of the impact of immune checkpoint inhibitors on platelet activation and aggregation. **2023**, 228, 152311 ○
- 120 Immunotherapeutic Strategies for Glioma Treatment. **2022**, ○
- 119 Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. **2023**, 157, 114057 ○
- 118 Immunotherapy of Lymphoma. **2022**, 1-24 ○
- 117 Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. ○ 1
- 116 PVR^{hi} Prognostic Biomarker Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma. **2022**, 12, 2953 ○
- 115 Targeted xCT-mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti-PD-1/L1 Response. 2203973 ○
- 114 The Glycosylation of Immune Checkpoints and Their Applications in Oncology. **2022**, 15, 1451 ○
- 113 EphA2 Promotes the Development of Cervical Cancer through the CXCL11/PD-L1 Pathway. **2022**, 2022, 1-17 ○
- 112 Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. **2022**, 23, 14496 ○ 1

111	Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma. 13,	o
110	PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer. 13,	o
109	Screening and identification of an anti-PD-1 nanobody with antitumor activity.	o
108	TGF- β A novel predictor and target for anti-PD-1/PD-L1 therapy. 13,	1
107	CH13L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis. 13,	o
106	ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation.	o
105	Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy. 13,	o
104	PD-L1 regulates inflammatory macrophage development from human pluripotent stem cells by maintaining interferon-gamma signal.	o
103	Exosomal LINC00460/miR-503-5p/ANLN positive feedback loop aggravates pancreatic cancer progression through regulating T cell-mediated cytotoxicity and PD-1 checkpoint. 2022 , 22,	o
102	Immune Checkpoint and Other Receptor-Ligand Pairs Modulating Macrophages in Cancer: Present and Prospects. 2022 , 14, 5963	o
101	Activation of cancer immunotherapy by nanomedicine. 13,	1
100	Diverse Neutrophil Functions in Cancer and Promising Neutrophil-Based Cancer Therapies. 2022 , 23, 15827	o
99	Current status and challenges of immunotherapy in ALK rearranged NSCLC. 12,	o
98	Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.	o
97	Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. 2022 , 3, 1513-1533	o
96	Regression in cutaneous melanoma: histological assessment, immune mechanisms and clinical implications. 2022 ,	o
95	The effect of Wnt/ β catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer. 2022 , 30, 99-116	o
94	PD-1 inhibition in aged podocytes and glomerular disease. 2023 , 103, 18-20	o

93	Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. 2023 , 100929	0
92	Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma. 2023 ,	0
91	Study on endogenous inhibitors against PD-L1: cAMP as a potential candidate. 2023 , 123266	0
90	Clustered regularly interspaced short palindromic repeats/Cas9-mediated gene editing. A promising strategy in hematological disorders. 2023 ,	0
89	Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. 2023 , 23,	0
88	PD-1 expression in transbronchial biopsies of lung transplant recipients is a possible early predictor of rejection. 13,	0
87	Diagnostic Accuracy of Slow-Capillary Endobronchial Ultrasound Needle Aspiration in Determining PD-L1 Expression in Non-Small Cell Lung Cancer. 2023 , 91, 1-8	0
86	PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia.	2
85	Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance specific cytotoxic activity against HIV Env+ cells in vivo. 2023 ,	0
84	Strahlentherapie und Immuntherapie. 2023 , 1-20	0
83	PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma. 2022 , 209, 621-628	0
82	Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer. 2022 ,	0
81	Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study. 2023 , 16, 41	1
80	The Performance of UMAP plus Linkage Compared with Daura-Clustering of Molecular Dynamics of the PD-1 Checkpoint Receptor. 2022 ,	0
79	Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. 2023 , 18, e0281143	1
78	Immunogenic Cell Death in Cancer. 2023 ,	0
77	Circulating Tumor Cells in Breast Cancer. 2023 ,	0
76	PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells. 2023 , 13, 221	0

75	Preclinical Basis of the Efficacy and Pharmacodynamics of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody with Potent Implications for Clinical Benefit.	o
74	Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective. 10,	1
73	Immune Checkpoint Inhibitors Programmed Cell Death-1/Programmed Cell Death-Ligand1 (PD-1/PD-L1) for Cancer Therapy.	o
72	Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress. 14,	o
71	S100a9 deficiency accelerates MDS-associated tumor escape via PD-1/PD-L1 overexpression. 2023 ,	o
70	A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration Approved PD-1 and PD-L1 Inhibitors. 2023 , 7, 125-139	o
69	Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment. 14,	o
68	Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes. 12,	o
67	Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma.	o
66	The Blessed Union of Glycobiology and Immunology: A Marriage That Worked. 2023 , 10, 15	o
65	Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma. 2023 , 2023, 1-17	o
64	Role of Monocyte-Derived Dendritic Cells (MoDCs) in Tumor Immune Response. 2023 , 1-18	o
63	p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells.	o
62	PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. 2023 , 133,	o
61	Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function.	o
60	Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS/STING pathway.	o
59	Epigenetics and immune cells in medulloblastoma. 14,	o
58	The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade. 2023 , 161, 114436	o

- 57 Metformin plays an antitumor role by downregulating inhibitory cells and immune checkpoint molecules while activating protective immune responses in breast cancer. **2023**, 118, 110038 ○
- 56 The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. **2023**, 162, 114646 ○
- 55 Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy. **2023**, 15, 2288 ○
- 54 Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis. **2023**, 183, 103922 ○
- 53 A comprehensive analysis of the expression and prognosis of STATs in human breast invasive carcinoma. ○
- 52 Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. **2023**, 12, 218 ○
- 51 LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis. **2023**, 14, 1
- 50 Recent advancement in breast cancer treatment using CAR T cell therapy:- A review. **2023**, 7, 100090 ○
- 49 Lipid-conjugated siRNA hitchhikes endogenous albumin for tumor immunotherapy. **2023**, 108210 ○
- 48 Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab. ○
- 47 Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. **2023**, 23, 227-233 ○
- 46 The Role of Hedgehog Signaling in the Melanoma Tumor Bone Microenvironment. ○
- 45 Regulation of programmed death ligand 1 expression by interferon- γ and tumour necrosis factor- α in canine tumour cell lines. ○
- 44 Killer to cure: Expression and production costs calculation of tobacco plant-made cancer-immune checkpoint inhibitors. ○
- 43 PD-L1, a Master Regulator of Immunity 2.0. **2023**, 24, 4385 ○
- 42 An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. 14, ○
- 41 Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy. **2023**, 13, ○
- 40 CD169 + sinus macrophages in regional lymph nodes do not predict mismatch-repair status of patients with colorectal cancer. ○

- 39 Inhibitors targeting epigenetic modifications in cancer. **2023**, 287-324 ○
- 38 Neuroendocrine Tumors and Immune System. **2023**, ○
- 37 An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. **2023**, 24, 5002 ○
- 36 Progression in immunotherapy for advanced prostate cancer. 13, 1 ○
- 35 Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?. 14, ○
- 34 Prognostic Significance of Circulating Basophil Counts in Patients Who Underwent Esophagectomy for Esophageal Cancer. ○
- 33 DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy. **2023**, 15, 1619 ○
- 32 Emerging phagocytosis checkpoints in cancer immunotherapy. **2023**, 8, ○
- 31 Causal relationships between gut microbiota and programmed cell death protein 1/programmed cell death-ligand 1: A bidirectional Mendelian randomization study. 14, ○
- 30 Promising Nanomedicines of Shikonin for Cancer Therapy. Volume 18, 1195-1218 ○
- 29 Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment. **2023**, 41, 620-636.e9 ○
- 28 Therapeutic Vaccination in Head and Neck Squamous Cell Carcinoma: A Review. **2023**, 11, 634 ○
- 27 Turning a Tumor Microenvironment Pitfall into Opportunity: Discovery of Benzamidoxime as PD-L1 Ligand with pH-Dependent Potency. **2023**, 24, 5535 ○
- 26 Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience. **2023**, 24, 5938 ○
- 25 Programmed Cell Death 1 checkpoint inhibitors as cancer therapies. 36, 8-16 ○
- 24 Single Drug Therapy of PD-1/PD-L1 Checkpoint Inhibitors for Advanced Urothelial Bladder Cancer. 36, 29-35 ○
- 23 Combi-TED: a new trial testing Tedopi[®] with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. **2022**, 18, 4457-4464 ○
- 22 Application status and future prospects of the PDX model in lung cancer. 13, ○

- 21 Guest Editorial: what can be done to improve cancer immunotherapies?. **2023**, 117, 631-633 ○
- 20 Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells. **2023**, 21, ○
- 19 An immune checkpoint-based signature predicts prognosis and chemotherapy response for patients with small cell lung cancer. **2023**, 117, 109827 ○
- 18 Molecular imaging for cancer immunotherapy. **2023**, 1, 3-17 ○
- 17 Do Elevated YKL-40 Levels Drive the Immunosuppressive Tumor Microenvironment in Colorectal Cancer? Assessment of the Association of the Expression of YKL-40, MMP-8, IL17A, and PD-L1 with Coexisting Type 2 Diabetes, Obesity, and Active Smoking. **2023**, 45, 2781-2797 ○
- 16 Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer. 14, ○
- 15 Preoperative neutrophil-to-lymphocyte ratio correlates with PD-L1 expression in immune cells of patients with malignant pleural mesothelioma and predicts prognosis. **2023**, 13, ○
- 14 High-Dimensional Spectral Cytometry Reveals Therapeutically Relevant Immune Subtypes in Gastric Cancer. ○
- 13 ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers. **2023**, 11, e006345 ○
- 12 Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response. **2023**, 9, ○
- 11 Palmitoyl transferases act as novel drug targets for pancreatic cancer. **2023**, 21, ○
- 10 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 9 Immune checkpoint therapy: current perspectives and future directions. **2023**, 186, 1652-1669 ○
- 8 Understanding HAT1: A Comprehensive Review of Noncanonical Roles and Connection with Disease. **2023**, 14, 915 ○
- 7 TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial. 13, ○
- 6 Clonogenicity-based radioresistance determines the expression of immune suppressive immune checkpoint molecules after hypofractionated irradiation of MDA-MB-231 triple-negative breast cancer cells. 13, ○
- 5 Immunotherapy. **2023**, 489-540 ○
- 4 Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities. ○

- 3 Fatty Acid Binding Protein 5 (FABP5) Promotes Aggressiveness of Gastric Cancer Through Modulation of Tumor Immunity. **2023**, 23, 340 ○
- 2 Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors. **2023**, 67, ○
- 1 Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy. **2023**, 22, ○